

China Shineway Pharmaceutical Group Limited 中國神威藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability) Stock Code: 02877

LEADING MODERN CHINESE MEDICINE PROMOTING HEALTH INDUSTRY

小儿清肺化痰颗粒



Contents

2	Corporate Information
3	Financial Highlights
4	Major Achievements and Awards
9	Chairman's Statement
11	Management Discussion and Analysis
25	Directors and Senior Management
29	Directors' Report
39	Corporate Governance Report
49	Audit Committee Report
50	Independent Auditor's Report
52	Financial Statements

Corporate Information

BOARD OF DIRECTORS

Executive Directors

Mr. Li Zhenjiang (Chairman of the Board) Ms. Wang Zhihua Ms. Xin Yunxia Mr. Li Huimin Ms. Lee Ching Ton Brandelyn (appointed on 1 October 2012)

Non-executive Director

Mr. Hung, Randy King Kuen

Independent non-executive Directors

Mr. Ren Dequan Ms. Cheng Li Mr. Sun Liutai

Audit Committee

Mr. Sun Liutai *(Committee Chairman)* Mr. Ren Dequan Ms. Cheng Li

Remuneration Committee

Ms. Cheng Li *(Committee Chairman)* Mr. Sun Liutai Ms. Xin Yunxia

Nomination Committee

Mr. Li Zhenjiang (*Committee Chairman*) Mr. Ren Dequen Mr. Sun Liutai

AUTHORIZED REPRESENTATIVES

Ms. Wang Zhihua Mr. Li Huimin

COMPANY SECRETARY

Ms. Wong Mei Shan

AUDITOR

Deloitte Touche Tohmatsu

REGISTERED OFFICE

Cricket Square, Hutchins Drive P.O. Box 2681, Grand Cayman KY1-1111 Cayman Islands

HEAD OFFICE

Luan Cheng, Shijiazhuang Hebei Province, The People's Republic of China ("PRC")

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Suite 5201, 52/F., Central Plaza 18 Harbour Road, Wanchai, Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Royal Bank of Canada Trust Company (Cayman) Limited 4th Floor, Royal Bank House 24, Shedden Road, George Town Grand Cayman KY1-1110, Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Computershare Hong Kong Investor Services Limited Shops 1712-1716 17th Floor, Hopewell Centre 183 Queen's Road East Wanchai Hong Kong

PRINCIPAL BANKERS

China Construction Bank (Asia)

The Hongkong and Shanghai Banking Corporation Limited

Bank of China, Zhong Shan Branch Shijiazhuang, Hebei Province

Bank of China, Lang Fang Branch Lang Fang City, Hebei Province

LEGAL ADVISERS

As to Hong Kong Law Woo Kwan Lee & Lo

As to Cayman Islands Law Conyers Dill & Pearman, Cayman

STOCK CODE

02877 (listed on the Main Board of The Stock Exchange of Hong Kong Limited)


WEBSITES

www.shineway.com.hk www.shineway.com


Financial Highlights

	2008	2009	2010	2011	2012
	2000	2005	2010	2011	2012
RESULTS					
Turnover	1,275,179	1,633,223	2,038,379	1,984,542	2,132,249
Gross profit	914,317	1,178,091	1,435,008	1,302,083	1,391,946
Profit before taxation	476,214	884,016	991,808	949,500	799,736
Profit attributable to shareholders	398,242	767,304	821,756	755,600	647,704
Basic earnings per share	RMB0.48	RMB0.93	RMB0.99	RMB0.91	RMB0.78
Dividends	206,750	305,990	330,800	305,990	264,640
ASSETS AND LIABILITIES					
Total assets	2,426,457	3,269,928	3,972,139	4,376,974	4,743,035
Total liabilities	(289,740)	(547,847)	(742,562)	(722,021)	(746,417)
Net assets	2,136,717	2,722,081	3,229,577	3,654,953	3,996,618
Non-controlling interests	-	_	_	(576)	(527)
Total equity	2,136,717	2,722,081	3,229,577	3,654,377	3,996,091

Profit Attributable to Shareholders



Gross and Net Profit Margins



Major Achievements and Awards of China Shineway in 2012

YEAR 2012

January

- China Shineway was included in the "Top 10 most competitive Chinese Medicine companies in the Chinese pharmaceutical industry for the year 2011" by Medicine Economic News
- China Shineway was awarded "The Best Employer of the year in China (2011) the Best Employer of the year in Shijiazhuang"
- China Shineway was honored as the "Hebei Model Enterprise for the integration of information technology and industrialization"
- Chairman Li Zhenjiang was honored as the "Outstanding Leader of Quality Management Program in Chinese Pharmaceutical Industry for 2012" by the China Quality Association for Pharmaceuticals

February

- Qing Kai Ling soft capsules received the "Readers Favorite Brand of Health Award" of the "2011 Jinbangtiming Award" by Zhejiang Elderly Newspaper
- Pediatric Qing Fei Hua Tan granule was honored with the title of "Hebei Quality Products in 2011"
- Huo Xiang Zheng Qi soft capsules and Wu Fu Xin Nao Qing Soft Capsule were honored with the title of "Well-Known Brands in Hebei for the year 2011"

April

- China Shineway Injection workshop team was awarded the honorary title of "Worker Vanguard" for the promotion of the private economy by the Hebei Federation of Trade Unions
- Chairman Li Zhenjiang was appointed as a member of the Steering Committee of Experts of the China pharmaceutical industry Policy Research Project by the Chinese Pharmaceutical Association

May

- China Shineway was included in the "Top 10 Enterprises in the Hebei Pharmaceutical Industry in 2011" by Hebei Province Pharmaceutical Industry Association
- China Shineway was named the major tax contributor in 2011 in the pharmaceutical industry in Hebei by the Hebei Pharmaceutical Industry Association

June

- China Shineway was awarded the title of "Innovative Enterprise in Hebei" by the Industrial Equipment Management Innovations Assessment Program in 2012
- China Shineway received the "Outstanding Contribution Nomination Award of advertisers" in the "Whistling Awards of the third classical propagation in 2011"
- Chairman Li Zhenjiang was awarded the "Imjin year Confucius and Confucianism Award" at the 2012 China (Qufu) International Confucius Cultural Festival

July

- China Shineway was honored as the "Hebei Model Project of the Corporate Culture Development"
- China Shineway was ranked position 32 in the top 100 pharmaceutical manufacturers in China pharmaceutical industry in 2011
- China Shineway received the first prize of the Science and Technology Progress Award of the "2011 Science and Technology Award of the Hebei Pharmaceutical Industry" for the standardization of the quality of traditional Chinese medicine injections and the high-tech industrialization Model Project
- China Shineway was named the outstanding enterprises of the national pharmaceutical industry quality management group activities in 2012 by the China Pharmaceutical Quality Management Association

- China Shineway were honored as the "High-tech Enterprises" Shineway Pharmaceutical Co., Ltd., Hebei Shineway Pharmaceutical Co., Ltd.
- China Shineway was honored as the most fascinating brand of the year in the China's pharmaceutical retail market (Huo Xiang Zheng Qi soft capsule)
- Six QC team of China Shineway were awarded as the "Outstanding Quality Management Team of Hebei Province in 2012"
- Nine QC team of China Shineway were awarded as the "Outstanding Quality Management Team of Chinese Pharmaceutical Industry in 2012"
- Five QC team won the second prize of published results of the 2012 annual national pharmaceutical industry quality management team
- Four QC team won the first prize of published results of the 2012 annual national pharmaceutical industry quality management team
- China Shineway was awarded the "Excellent Enterprise for Quality Management Team Program in Chinese Pharmaceutical Industry for 2012"
- China Shineway was awarded the "Outstanding Leader for Quality Management Team Program in Chinese Pharmaceutical Industry for 2012"
- China Shineway received the first prize of the Science and Technology Progress Award for the standardization of the quality of traditional Chinese medicine injections and the high-tech industrialization Model Project
- Chairman Li Zhenjiang was selected as the Person of the Year for 2012, China Medicine Economy, by the Medicine Economic News/ PICO (Group)

August

- China Shineway was honored as the "2010-2011 Hebei Civilized Unit" by the CPC Hebei Provincial Party Committee and Provincial Government for the outstanding contributions in promoting coordinated economic and social development
- China Shineway was honored as the Standard Model Enterprise in Hebei
- China Shineway received the third prize of the Patents Award of the Hebei Cultivation Project of the Advantage of Intellectual Property – a manufacturing method to increase the content of amino acid of the Qing Kai Ling
- Chairman Li Zhenjiang was appointed as the Deputy Head of both the Expert Group and Leading Group of the development of the pilot city for the comprehensive reform of the national development of Traditional Chinese Medicine (TCM) by Shijiazhuang Municipal People's Government Office

September

- China Shineway was included in the "Top 100 Hebei manufacturing companies in 2012"
- China Shineway was honored as the Leading Enterprise (the "Vanguard Enterprise") of the Hebei pharmaceutical manufacturing enterprises in 2012
- China Shineway was the Sponsor of the Experts Tour for the Rational Use of Traditional Chinese Medicine Injection in China
- Chairman Li Zhenjiang was appointed as a part-time professor of the Party University of Shijiazhuang City Committee of CPC

October

• China Shineway received the main prize of the 2012 China Advertising Great Wall Award at the 19th China International Advertising Festival

December

- China Shineway received the first prize of the All-China Federation of Industry and Commerce (ACFIC) Science and Technology Progress Award for the standardization of the quality of traditional Chinese medicine injections and the high-tech industrialization Model Project
- China Shineway soft capsules pelleting team was named the 2012 National Quality Trustworthy team
- China Shineway was honored as the Advanced Unit (Customer Satisfaction Enterprise) for the implementation of the 2012 Customer Satisfaction Project in Hebei by Hebei Association for Quality
- China Shineway received the Excellence Award of the All-China Federation of Industry and Commerce (ACFIC) Science and Technology Progress Award (Shujin Tongluo granules)
- Huo Xiang Zheng Qi Soft Capsule, Qing Kai Ling soft capsules, Liyan detoxification granules, Wu Fu Xin Nao Qing Soft Capsule and Pediatric Qing Fei Hua Tan granules were named Customer Satisfaction Products in 2012 by Hebei Association for Quality

Chairman's Statement

Dear Shareholders,

On behalf of the board of directors (the "Board") of China Shineway Pharmaceutical Group Limited (the "Company" or "China Shineway"), I am pleased to present the annual report of the Group for the year ended 31 December, 2012.

Confronted with the complex market situation in 2012, with the Government medical reform, the implementation of essential drugs tendering requirements, the implementation of new GMP requirements, the prices reduction market and the costs increase of raw and supplementary materials, labor costs and other costs, the Company made appropriate judgment and decision by implementation of the corresponding sales structure reform to cope with the complex market situation. We continued our sales reform, adjusted our sales and marketing model, leveraged on our Shineway brand advantage and product advantage, continued our sales network building at the terminal level, replaced unqualified sales managers and strengthened the resources consolidation of the Group. In the year of sales structure reform, with the support of every staff of the Company, we reinforced our comparative advantage, thought out of the box, faced the challenge directly and continued to move forward in the year of transformation. With all the challenge in front of us, our operating income increased slightly while the profit for the year fell by 14.3% as compared with last year.

The Group recorded sales revenue of RMB2.13 billion in 2012, representing a year-on-year increase of approximately 7.4%. The Group's profit for the year amounted to approximately RMB650 million in 2012, representing a year-on-year decrease of approximately 14.3%. The sales of injection products recorded an increase of approximately 8.4% over the previous year. The sales of soft capsule products recorded an increase of approximately 2.5% over the previous year. The sales of granule products recorded an increase of approximately 7.8% as compared with the previous year.

The new injection workshop has already obtained the new GMP certification in 2012. The construction of the main building of the new Chinese medicine extraction workshop is now completed and the new GMP certification will be obtained in 2013. By the end of 2013, our manufacturing workshops and subsidiaries will obtain the corresponding new GMP certifications accordingly. We are also the first company obtained the new GMP certification in China.

The new injection workshop at Beijing East Yanjiao Development Zone in Langfang is now under construction, the new GMP certification is expected to be obtained in 2013.

The existing research projects of the Group are progressing steadily, with six invention patents authorized by the State Intellectual Property Office during the year. Sai Luo Tong and a number of existing research projects have entered into or completed clinical trials. Sai Luo Tong is the only new herbal medicine products in the PRC to be developed through international cooperation and has a bright market prospect. Following its launch in the market, the product is expected to open up a new stance for Chinese medicine in the international market.

Chairman's Statement

The infrastructure construction of Sichuan Qionglai Project is underway, paving the way for the Group's future business and capacity expansion in western China. With the completion of various projects and put into operation successively, we have laid down a solid foundation for the Group to meet the sales demand in the next 5 to 10 years.

China Shineway is now among the top four manufacturers in the Chinese medicine industry with the highest income from the core manufacturing business in 2012. Our "Shenmaio" trademark was awarded as China Famous Trademark, together with "Shineway" and "Wu Fu", the Group has a total of three China famous trademarks now. China Shineway received many awards including the "Top 10 most competitive Chinese Medicine companies in the Chinese pharmaceutical industry", the "Best Employer of the year in China", the "Outstanding Enterprises of the National Pharmaceutical Industry Quality Management Group Activities in 2012", the "Outstanding Leader of Quality Management Program in Chinese Pharmaceutical Industry for 2012" as well as the first prize of the Science and Technology Progress Award for the standardization of the quality of traditional Chinese medicine injections and the high-tech industrialization Model Project.

Under the new situation of the pharmaceutical industry in 2013, we will continue the sales structure reform according to the policy direction of the government and the pharmaceutical industry. To reinforce the competitiveness of the Group, we will adjust our research and development, sales and marketing as well as mergers and acquisition strategies according to the market direction and trend in 2013. To improve the cost efficiency, we will establish program to control our costs, improve the production efficiency and save the energy for production. For the consolidation on efficiency, we will strengthen the resources allocation and integration, optimize the work flow and promote the internal market management program for the Group. To strengthen the leadership position of China Shineway in the traditional Chinese medicine industry, we will learn from outstanding enterprises in the industry and set specific targets to increase our staff efficiency per capita and to perform better than the industry benchmark.

Outstanding pharmaceutical enterprises will continue to accelerate the pace of mergers and acquisitions in 2013, so as to expand their strengths and scale of operation. We will continue to look for appropriate projects to expand our market and operation scale both at home and abroad.

China Shineway's accomplishments are inseparable from our staff's hard work. On behalf of the Board, I would like to extend my sincere gratitude and high respect to our diligent staff for their dedication and efforts during the year.

Li Zhenjiang Hong Kong, 26 March 2013

BUSINESS REVIEW

2012 is a critical year of refinement of medical reform in the PRC. Many policies related to drugs and medicine including the pharmaceutical industry plan, policy regarding medicine bid and the reform of public hospitals and pricing policy of drugs, have launched and are closely attended by the market. These events imposed challenges to the Group and the Group experienced a rise in its turnover and a decline in profit. For the year 2012, the Group recorded a turnover of RMB2,132,249,000, an increase of 7.4% from previous year. Sales by product form for the year are set out as follows:

	Sales	Growth	Product
	(RMB)	Rate	Mix
Injections	1,238,486,000	8.4%	58.1%
Soft Capsules	446,739,000	2.5%	21.0%
Granules	366,300,000	7.8%	17.2%
Other product formats	80,724,000	21.8%	3.7%

The Group's profit attributable to owners of the Company for 2012 is RMB647,704,000, representing a drop of 14.3% from year 2011. The decrease in profit was mainly caused by price adjustments of certain products and increase in expenses.

Injection Products

During 2012, the Group sold RMB1,238,486,000 of injection products, an increase of 8.4% from year 2011. Amongst these injection products, Qing Kai Ling injection remained the key product of the Group. Injection products accounted for 58.1% of the Group's turnover in 2012, while they contributed 57.6% of the turnover in prior year.

There are continued market demands for Chinese medicine injection products. The Group's annual production capacity for injection product is now 2 billion vials. The Group believes that it is currently the largest Chinese medicine injections manufacturer in the PRC in terms of sales volume and production capacity. A number of the Group's injection products are designated by regulatory agencies as "Good Quality/Good Price" products. Meanwhile, the construction of the new injection production workshop has completed with the new GMP certification gained and is expected to formally operate in 2013. The injection production capacity will then be increased from the present of approximately 2 billion vials to 3.2 billion vials per annum.

In July 2009, the State Food and Drug Administration ("SFDA") has developed the "Principles on Re-Evaluating Chinese Medicine Injection Safety-Quality Control" and series of relevant laws and regulations to increase the production and quality control standards of Chinese medicine injection. The re-evaluation of Chinese medicine injection has been started. The Group believes the state re-evaluation will significantly enhance the production technologies and quality standards of Chinese medicine injection. Those production companies with lack of production technologies, low quality control, low production rate and unable to start the re-evaluation of Chinese medicine injection will be eliminated. Entry barrier to Chinese medicine injection would be significantly increased and hence quality will be increased substantially. The good curative effect of Chinese medicine injection will be recognized by the market and the Group's quality, cost, size and brand will become more prominent.

In the coming year, the Group will continue to expand our point of sales and further strengthen promotion efforts of end user market to ensure better growth of our injection products.

Soft Capsule Products

During the year, the Group recorded RMB446,739,000 on sales of soft capsule products, an increase of 2.5% from last year. The increase was mainly driven by the rise in sales of Wu Fu Xin Nao Qing Soft Capsule and Qing Kai Ling Soft Capsule as compared with last year.

Soft Capsule products accounted for 21.0% of the Group's turnover in 2012, as compared to 22.0% in last year. The Group's current production capacity for soft capsules is 3.5 billion capsules per annum. The Group believes that it is currently the largest Chinese medicine soft capsules manufacturer in the PRC in terms of sales volume and production capacity.

The Group will continue to strengthen our brand promotion and marketing effect on our soft capsules products to advance their business growth in the coming year.

Granule Products

Sales of granule products in 2012 increased by 7.8%, amounted to RMB366,300,000. The increase was mainly attributable to the year-on-year sales increase of Fen An Ka Min Granule, Pediatric Anfen Huang La Min Granule and Huamoyan Granule.

Granule products accounted for 17.2% of the Group's turnover in 2012 as compared to 17.1% in 2011.

The Group's new granule and tablet workshop commenced production in previous year with annual production capacity for granule products of 3.4 billion bags per annum. The Group believes that it is currently the largest Chinese medicine granules manufacturer in PRC in terms of sales volume and production capacity.

Other Products

Sales of other products in 2012 increased by 21.8% compared to last year, amounted to RMB80,724,000. The increase was mainly attributable to the increase in sales of Fufang Gancao Pian, Fufang Anfen Wanan Pian and Naolibao Tablet as compared with last year.

Key Products

The six key products of the Group were Qing Kai Ling Injection, Shen Mai Injection, Shu Xie Ning Injection, Wu Fu Xin Nao Qing Soft Capsule, Huo Xiang Zheng Qi Soft Capsule and Pediatric Qing Fei Hua Tan Granule.

Qing Kai Ling Injection – a widely used anti-viral medicine for treatment of viral diseases including respiratory tract infection, viral hepatitis, cerebral haemorrhage and cerebral thrombosis

Our Qing Kai Ling Injection increase in sales from last year and is the major contributor to the Group's turnover.

Qing Kai Ling Injection is listed in the "National Catalogues of Medical Insurance and Occupational Injury Insurance". It is designated by the State Administration of Traditional Chinese Medicine as an "Indispensable Chinese Medicine for the Emergency Wards of Chinese Hospitals". It is also recommended by the Ministry of Health of the PRC for treating Human Transmitted Avian Flu and the A(H1-N1) Flu. The product has broad clinical applications. Qing Kai Ling Injection produced by the Group is a famous anti-viral medicine and has been selected as the National Reserved Medicine, also named as "Good Quality/Good Price" and "State High-Tech Product" by the authorities.

Qing Kai Ling Injection has been included by the Ministry of Health in the Essential Drug List in 2010. The Group believes with vigorously investment in building the New Rural Cooperative Medical Care System by the State, Urban Resident Basic Medical Insurance and implementing the Essential Drug List by the PRC, as well as the Measures for the Administration on the Clinical Application of Antibacterial Medicines to be issued by the Ministry of Health of the PRC, which will restrict the overuse of antibacterial medicines in clinics, market demand of heat clearing and anti-toxic Chinese medicine, especially for Qing Kai Ling Injection, is expected to grow vastly. The Group believes that it is the largest manufacturer of Qing Kai Ling Injection in the PRC based on sales volume and sales amount. The Group will further enhance market coverage and penetration of end networks, as well as to strengthen marketing and promotion effort at the points of sales. Qing Kai Ling Injection will sustain steady growth.

天義子	清機	清城
NAL DA	灵注 射液	灵注 射液 論

Shen Mai Injection – for treatment of coronary heart disease, viral myocarditis and pulmonary heart disease

In 2012, sales of Shen Mai Injection recorded an increase compared with last year.

Shen Mai Injection is included in the National Catalogues of Medical Insurance and Occupational Injury Insurance and the Essential Drug List. It is also included in the recommendation of the Ministry of Health of the PRC for treating Avian Flu and the A(H1-N1) Flu.



The Group believes that it is the largest manufacturer of Shen Mai Injection in the PRC based on sales volume. The Group will strive to further expand market share and penetration for Shen Mai Injection to generate further growth in the coming years.

Shu Xie Ning Injection – for treatment of cardio-cerebrovascular disease

In 2012, sales of Shu Xie Ning Injection increased compared with last year.

Shu Xie Ning Injection is designated as a "Good Quality/ Good Price" product by the PRC authorities. It is included in the National Catalogues of Medical Insurance and Occupational Injury Insurance and is one of the first tier medicines for treatment of cardiovascular diseases. The Group will continue to further enhance market coverage and penetration, foster marketing effort at the points of sales, and look for strategic distributors and rationalize distribution channels to achieve continuous growth.





Wu Fu Xin Nao Qing Soft Capsule – for prevention and treatment of coronary heart disease and cerebral arteriosclerosis

Sales of Wu Fu Xin Nao Qing Soft Capsule in this year increased compared with last year.

Wu Fu Xin Nao Qing Soft Capsule is ranked among the top ten cardiovascular Chinese medicines in the country. The "Wu Fu" trademark was certified as a "China Famous Trademark". It is also one of the lowest in cost of average daily dosage among similar cardiovascular medicines. The Group will continue to strengthen our effort on promoting the "Wu Fu" brand and deepen our end-user market coverage and exercise more support to our distributors by increasing promotional activities to broaden its sale.

Huo Xiang Zheng Qi Soft Capsule – for prevention and treatment of heat stroke, stomachache, nausea and diarrhoea, acclimatization sickness

In 2012, sales of Huo Xiang Zheng Qi Soft Capsule decreased compared with last year.

Huo Xiang Zheng Qi Soft Capusles is listed in the National Catalogues of Medical Insurance and Occupational Injury Insurance. It is also recommended by the Ministry of Health of the PRC for Avian Flu and the A(H1-N1) Flu. Due to its effective efficacy and the high bioavailability of soft capsule, Huo Xiang Zheng Qi Soft Capsule is a very popular OTC Chinese medicine.





Pediatric Qing Fei Hua Tan Granule – for children infected by respiratory related disease

Sales of Pediatric Qing Fei Hua Tan Granule in 2012 dropped compared with last year.

Pediatric Qing Fei Hua Tan Granule has superb curative effect and has become a famous brand of children coughing medicine. The Group will continue to increase advertising and joint promotional campaign with chain drug stores to ensure sales growth momentum of this product. The "Shen Miao" trademark was certified as a "China Famous Trademark".

The Group will continue to expand end market coverage. Furthermore, we will expedite partnership with strategic distributors and chain drugstores, and increase promotion to strive for better growth of Huo Xiang Zheng Qi Soft Capsule.

Emerging Products

Huang Qi Injection – for treatment of viral myocarditis, heart malfunction and hepatitis In 2012, sales of Huang Qi Injection increased compared with last year.



Huang Qi Injection is listed in the National Catalogues of Medical Insurance and Occupational Injury Insurance. Viral myocarditis has become more prevalent in recent years. With a proven efficacy on such illness, Huang Qi Injection has strong market potential. The Group will continue to further enhance market coverage and penetration and growth in sales of Huang Qi Injection is expected in the coming years.

Qing Kai Ling Soft Capsule – for treatment of high fever, viral influenza and respiratory tract infection

Sales of Qing Kai Ling Soft Capsule in current year increased compared with last year.

Qing Kai Ling Soft Capsule is both a prescription and non-prescription medicine.

Benefited greatly by the synergistic effect of Qing Kai Ling Injection, the Group will further expedite partnership with strategic distributors and chain drug stores, and increase promotion effort to ensure sales momentum of this product.



Huamoyan Granule – for treatment of both acute and chronic synovitis and treatment after joints surgery

Sales of Huamoyan Granule in current year increased compared with last year.

Synovitis is currently a relatively common type of arthropathy which widely affects the mid-aged group, senior citizens, athletes and patients after joint surgeries. Huamoyan Granule produced by the Group is the first innovative medicine approved by the State Food and Drug Administration for the treatment of synovitis. It is an original and self-developed product with proprietary formulations, marking a milestone for the treatment of synovitis and bringing the same to a new height. With the Group's intensified presence in the end market of hospitals and the advancement of the promotion to professionals and academics, this product has obtained sound performance and returns from the market with an on-going momentum for growth.

Shujin Tongluo Granule – for treatment of spondylosis, neck stiffness and symptoms such as pains of neck, shoulder and back

During the year, sales of the Group's Shujin Tongluo Granule increased compared with last year.

The increase in the number of people who tilt down their heads during work has resulted in a growing prevalence of spondylosis nowadays, and the disease has also shown a trend of younger. Shujin Tongluo Granule produced by the Group is currently the only proprietary and multi-target Chinese medicine in the market which addresses both symptoms and root causes to continuously mitigate the symptoms of spondylosis. It also has a noticeable effect on curing both nerve root type and vertebral artery type of spondylosis, hence offering clinical doctors with a new choice for the treatment of spondylosis. After the ongoing academic promotion in recent years, Shujin Tongluo Granule has achieved strong market growth.

Jiangzhi Tongluo Soft Capsule – for treatment of symptoms such as hyperlipidemia, chest and hypochondrium pain and chest tightness

During the year, sales of Jiangzhi Tongluo Soft Capsule increased compared with last year.

Jiangzhi Tongluo Soft Capsule produced by the Group is a national key new product jointly certified by four ministries and commissions, including the Ministry of Science and Technology of the PRC. It is used for the revitalisation of blood and "Qi" circulation and for lowering blood cholesterol. Jiangzhi Tongluo Soft Capsule is superior to the existing blood cholesterol drugs in terms of effectiveness, and its liver protection ability provides what other similar clinical products lack, and is therefore a clear choice for patients undergoing long-term hyperlipidemia treatment. The Group will continue to promote the product to professionals and academics, provide physicians with information regarding the product and increase brand awareness so as to establish it as the best brand among other cholesterol-regulating drugs.

RESEARCH AND DEVELOPMENT

Currently, there are various research projects undergoing pharmaceutical and clinical trial, including 3 of which are for the treatment of cardiovascular diseases, 1 for the treatment of gynaecological diseases, 1 for the treatment of orthopedics, 2 for the treatment of cancer and a joint research project with a university in Australia to develop new medicines for the treatment of Alzheimer's disease. The Group has 12 launched Chinese medicine injection products which are now under launched product re-evaluation. A special project team is established to explore new products investment opportunity studies.

PATENT APPLICATIONS

The Group continued to strengthen the protection of its intellectual property rights. During 2012, the Group received 6 invention patents from the Intellectual Property Office of the PRC.

As at the date of the Annual Report, the Group has obtained 28 patents for our inventions, and a total of 23 patent applications are pending for approval.

STATE PROTECTED CHINESE MEDICINES

As of 31 December 2012, the Group had 5 products listed as State Protected Chinese Medicines, including Jiangzhi Tongluo Soft Capsule, Xuanmai Ganjie Lozenge, Jianyang Tablets, Yin Zhi Huang Injection and Shujin Tongluo Granule.

PROSPECT

2012 is a critical year of refinement of medical reform in the PRC, to encourage and support the development of medicine industry will be the trend of future policy guidance with the advance of medical reform and the introduction of related policies of the Twelfth Five-Year Plan. The policy will be the core factor determining the growth of medicine industry in the short run. Every leading enterprise in different subdivided fields will continue to grow through sharing a relatively speedy expansion in the industry, seizing the market share by eliminating companies and mergers and acquisitions. In following years, medicine industry will maintain a steady growth, the concentration of the industry will keep increasing, medicine tendering and purchasing will be ruled and adjusted, the government will strengthen the control on medicine price, such that the sale model under the new medical reform will be changed, competition in the pharmaceutical market is getting more and more intensified and the competition pattern would be changed, which will create both opportunities and challenges for enterprises.

According to the Twelfth Five-Year Plan of Chinese Medicine Enterprise Development, it is believed that a group of renowned Chinese medicine enterprises will be developed via the enlarged investments and the development of a more comprehensive investment safeguard system. The PRC government supports the development of Chinese medicine industry, and will keep heightening its support for the Chinese medicine industry to facilitate its development into a modern Chinese medicine industry. As an important category of Chinese medicine, Chinese medicine injections are in line with the development direction of modern Chinese medicine and are bound to benefit from the support and attention given by the government to the Chinese medicine industry.

Accelerated implementation of the new version of GMP could help to establish a more completed system of medicine production and supply, elevate the competition threshold in the industry and eliminate backward productivities, speed up the upgrading of the industry and promote maximum allocation of resources in medicine industry to dominant enterprises. Shineway's all under-processing formulations have obtained the pioneer approval under the new version of GMP, which build the leading position of the Group in the Chinese medicine industry.

With the rapid development of the economy and continuous increasing of per capita income, accelerated construction of the national medical insurance system, further expansion of basic health insurance coverage and continuous push in the implementation of basic medicine in China, the whole pharmaceutical market has been expanded and constantly improved the average medicine consumption level. Shineway made active respond to the changes of the new policy and the competitive landscape of the medical reform by making full use of industrial policy, making innovation in marketing mode, intensifying research and development of new drugs, merging and integrating advantage resources of the industry, strengthening the terminal quality construction and marketing depth, firmly pushing forward the building of grassroots market, expanding the development in the middle to high-end market, and basing on the formulation of the two core driving forces, namely, marketing and R & D, increasing scale sales and market share as well as purchasing high efficiency of management and profit through various management methods such as creative operation and lower cost with higher efficiency, which will bring the maximum interest and return for Shineway and its shareholders.

GROWTH STRATEGIES

The Group shall consistently implement the following growth strategies, together with our strong management team and our enormous manufacturing capacity to attain higher growth and return:

1. Expanding Manufacturing Capacity

Construct new workshops and make modifications of the existing workshops, expand Chinese medicine extraction capacity of injections and granules. The new granule and tablet workshop located in Shijiazhuang had completed its construction and commenced production in last year. The construction of our new injection workshop has completed with the new GMP certification gained and is expected to formally operate in 2013. Our new extraction workshop has completed its construction and is expected to commence by the end 2013. At the appointed time, our extraction capacity will increase from currently 10,000 tons to 20,000 tons and our injections production capacity will increase from currently 2 billion vials per annum to 3.2 billion vials per annum.

2. **Product Strategies**

- Target on three high growth market segments the middle and old aged, children and anti-viral medicines.
- Further increase sales contribution from core products (namely Qing Kai Ling Injection, Shen Mai Injection, Shu Xie Ning Injection, Wu Fu Xin Nao Qing Soft Capsule, Huo Xiang Zheng Qi Soft Capsule and Pediatric Qing Fei Hua Tan Granule).

- Continue to nurture emerging products (such as Huang Qi Injection, Qing Kai Ling Soft Capsule, Huamoyan Granule, Shujin Tongluo Granule and Jiangzhi Tongluo Soft Capsule).
- Increase investments in research and development to form a pipeline of innovative products manufactured by advanced technology, expand the product cluster of China Shineway.

3. Marketing Strategies

- Continue to expand sales covering the "Primary Medical Institutions" (county health centers, clinics and drug stores and city healthcare centers and pharmacists) to strengthen sales support and management.
- Increase in participation of Essential Drugs and other drugs bidding events, extend the chance of successful bid. Improve the market penetration of China Shineway's existing market and expand new market shares.
- Reinforce educational activities in main cities' drug stores and middle-high end hospitals, carry out academic forums, provide trainings to salesmen and to establish specialist network. Improve public awareness of China Shineway's products in both brand and academic perspective.
- Carry out marketing through refining our marketing strategy and improving the brand awareness and fundamental value of our products.

4. Merger, Acquisition and Investment Strategies

- Leverage on the re-integration opportunity of the pharmaceutical market brought along with the new healthcare reform, and the Company's brands, sales network and management experience to offset the inadequacies in the Company's existing products, sales and production capacity, integrate the resources in the market and propel the Company into high-speed development.
- Priority is given to product with huge market potential and relatively exclusive strains of medicine.
- Priority is given to enterprises with proprietary Chinese medicine injections, State Protected Chinese Medicine, patented medicine, exclusive medicine and national medicine.

FINANCIAL ANALYSIS

Turnover

In 2012, the Group recorded an increase in turnover of 7.4% from last year. Sales of injection products reached RMB1,238,486,000, up 8.4% as compared with 2011. Sales of injection products now account for 58.1% of the Group's turnover. Sales of soft capsule products were RMB446,739,000, representing an increase of 2.5%. Soft capsule products now account for approximately 21.0% of the Group's turnover. Sales of granule products amounted to RMB366,300,000, an increase of 7.8% from last year. Granule products now account for 17.2% of the Group's turnover. Sales of the Group's products of other formats were RMB80,724,000 which approximates to 3.7% of the Group's turnover.

During the year, turnover of medicines for cardiovascular diseases, anti-viral medicines, medicines for curing respiratory system and medicines for treating other illness respectively accounted for 48.1% (2011: 47.4%), 28.6% (2011: 28.7%), 6.2% (2011: 7.6%) and 17.1% (2011: 16.3%) of the Group's total turnover respectively in 2012.

Turnover of prescription and non-prescription medicines of the Group were RMB1,707,192,000 and RMB425,057,000, accounting for approximately 80.1% and 19.9% of the total turnover respectively in 2012. As at 31 December 2012, the Group had over 60 products that were included in the Essential Drug List.

Cost of Sales

Cost of sales in 2012 was RMB740,303,000, amounting to 34.7% of total turnover. Direct materials, direct labor and other production costs accounted for approximately 72.0%, 8.7% and 19.3% of total cost of sales.

Gross Margin

For 2012, average gross margins of injection products, soft capsule products and granule products were 67.9%, 70.4% and 52.9% respectively. Overall gross margin was slightly down from 65.6% of last year to 65.3% due to the increase in cost of labor, cost of energy resources and depreciation of fixed assets, together with the price adjustments of certain products.

Other Income

Other income mainly includes government subsidies of RMB76,021,000 (2011: RMB120,471,000). The government subsidies mainly represented incentives received from government for investments in relevant regions in PRC by the Group.

Investment Gain

Investment gain mainly includes interest income from bank deposits and investments in debt securities of RMB31,553,000 (2011: RMB41,114,000) and RMB48,454,000 (2011: RMB27,409,000) respectively.

Distribution Costs

Distribution costs have increased by 65.7% and accounted for 19.9% of turnover in 2012 as compared to 12.9% in last year. It was mainly due to the increase in advertising expenses and distributor promotion expenses. Advertising expenses and distributor promotion expenses accounted for 9.3% (2011: 5.4%) and 5.8% (2011: 2.5%) of the Group's turnover respectively.

Administrative Expenses and Research and Development Costs

Administrative expenses and research and development costs have increased by 11.9% from last year, representing 15.0% (2011: 14.4%) of the Group's turnover. Rise in administrative expenses was mainly due to increase in salary and staff benefits expenses. Administrative expenses also comprised of non-productive depreciation expenses of fixed assets which accounts for 0.9% of the Group's total turnover in 2012 (2011: 1.2%). Research and development expenses have increased by 18.6% from last year, accounted for 3.2% of the Group's turnover in 2012 as compared to 2.9% in 2011.

Income Tax Rate

Under the Law of the People's Republic of China on Enterprise Income Tax (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25% from 1 January 2008 onwards.

Certain subsidiaries which are operating in Western China or recognized as High and New-tech Enterprise have been granted tax concessions by the local tax bureau and are entitled to PRC EIT at concessionary rate of 15% for both years. The tax concessions granted to certain subsidiaries operating in the Western China will expire in 2020.

Dividends

Details of dividends and dividend policy are set out in the director's report on page 29 of this annual report.

Capital Structure

As at 31 December 2012, there was no change in the capital structure and issued share capital of the Group.

Liquidity and Financial Resources

As at 31 December 2012, bank deposits of the Group approximately amounted to RMB2,212,391,000 (2011: RMB2,172,812,000), of which RMB2,155,943,000 (2011: RMB2,076,407,000) were denominated in RMB, others being equivalent to RMB56,300,000 and RMB148,000 (2011: RMB96,230,000 and RMB175,000) were denominated in Hong Kong Dollars and United States Dollars respectively. Except for trade and other payables, the Group did not have any other liabilities.

The Directors believe that the financial position of the Group is healthy, with sufficient financial resources to meet the requirement for future development.

Bills and Trade receivables

As at 31 December 2012, bills and trade receivables increased by 24.0% and 52.2% respectively as compared to the balance as at 31 December 2011. This is due to the increasing preference of customers to settle orders of goods with bank bills to save financing costs in light of the tightening of lending. Turnover days of bills and trade receivables were 77.5 days and 2.9 days (2011: 61.4 days and 1.9 days respectively).

Inventories

As at 31 December 2012, inventories in the amount of RMB203,965,000 decreased by 27.9%, as compared to the balance as at 31 December 2011. As at 31 December 2012, raw materials, work in progress and finished goods accounted for 46.3%, 21.7% and 32.0% (2011: 48.9%, 20.2% and 30.9%) of inventories respectively. Turnover of finished goods inventories in 2012 was 37.7 days as compared to 35.6 days in 2011.

Property, Plant and Equipment

As at 31 December 2012, property, plant and equipment amounted to RMB1,398,248,000 increased by 26.2%. It was mainly due to the new construction works of plants located in Shijiazhuang, Langfang and Sichuan. Among which comprised injection workshop projects amounted to approximately RMB86,641,000; extraction workshop projects amounted to RMB93,238,000; new administrative buildings and peripheral facilities amounted to approximately RMB72,807,000 and power station project amounted to approximately RMB17,566,000. Besides there was also new additions to plant and machineries of approximately RMB52,152,000 during the year.

Interest in an associate

In September 2012, the Group acquired 33.24% equity interest of Jilin Jianjin Pharmaceutical Company Limited ("JJPCL") and since then JJPCL became an associate of the Group. JJPCL was incorporated in PRC with principal activities in manufacturing and selling of Chinese medicine.

Goodwill

Goodwill is related to the Group's acquisition of the remaining 20% ownership equity interests of Shineway Pharmaceutical Sales Co., Limited in 2005, and the acquisition of 100% equity interests of Shineway Zhangjiakou and Shineway Pharmaceutical (Sichuan) Company Limited (formerly known as Sichuan Kalituo Pharmaceutical Limited) in 2010.

Bills and Trade Payables

As at 31 December 2012, turnover days of bills and trade payables were 11.7 days and 127.5 days (2011: 16.8 days and 114.9 days).

Loans and Bank Borrowings

The Group did not have any loans or bank borrowings as at 31 December 2012 (2011: Nil), except for bank deposits of RMB19,860,000 (2011: RMB27,839,000) were pledged to bank to secure bills payables of RMB19,731,000 (2011: RMB27,839,000). Hence, the Group's gearing ratio based on interest bearing debt for the year is Nil (2011: Nil).

Pledge of Assets

At the time of settlement as at 31 December 2011, the Group secured the bills payables of RMB19,731,000 (2011: RMB27,839,000) by pledging bank deposits amounting RMB19,860,000 (2010: RMB27,839,000).

Contingent Liabilities

The Group did not have any contingent liabilities as at 31 December 2012 (2011: Nil).

Exposure to Fluctuations in Exchange Rates

Substantially all of the business transactions and liabilities of the Group are denominated in Renminbi and Hong Kong Dollars. The Group adopts a conservative financial policy and a majority of its bank deposits are in Renminbi and Hong Kong Dollars. The exchange loss for the year was arising from the change in exchange rate between Renminbi and Hong Kong Dollars. As at 31 December 2012, the Group did not have any bank liabilities, foreign exchange contracts, interest or currency swaps or other financial derivatives for hedging purpose.

Employees

As at 31 December 2012, the Group had 3,758 (2011: 4,063) employees. Remuneration was determined and reviewed based on fair principles with reference to market conditions and individual performance. The Group also provided other benefits to its employees, including medical insurance and retirement benefits. The Group's employees in Hong Kong were also enrolled in the Mandatory Provident Fund Scheme.

DIRECTORS

Executive Directors

LI Zhenjiang (李振江), aged 57, is an executive director and one of the founders of the Group. Mr. Li obtained an EMBA degree from the Yangtze Commercial Institute. Mr. Li joined the predecessor of the Group in 1974 and has been the Chairman and President of the Group and its predecessor since 1984 with responsibility for business development and strategy. He has more than 20 years' experience in the operation and management of modern Chinese medicine enterprises. Mr. Li takes charge of the overall management of the Group and is also specifically responsible for the Group's research and development activities. Mr. Li is a Representative to the 10th and 11th National People's Congress. He was named as an Outstanding Entrepreneur in the PRC Pharmaceutical Industry in 1994 and has received a National Wu Yi Labour Award and special subsidies of the State Council. Mr. Li is the vice-chairman of the PRC Chinese Medicine Association. Mr. Li is also directors of several members of the Group.

WANG Zhihua (王志華) (alias 王志花), aged 57, is an executive director and one of the founders of the Group. Ms. Wang graduated from Hebei Province Finance School in 1978 where she majored in industrial accountancy. Ms. Wang is primarily responsible for the Group's financial strategy and management. Ms. Wang joined the predecessor of the Group in 1982, where she focused on financial matters. She was the Deputy General Manager (finance and management) of Shineway Medical immediately prior to the corporate reorganisation in preparation of the listing of the Company in 2004. Ms. Wang has more than 20 years' experience in financial management in the industry with the Group.

XIN Yunxia (信蘊霞), aged 49, is an executive director and one of the founders of the Group. Ms. Xin graduated from the Yangtze Commercial Institute with an EMBA degree. Ms. Xin is primarily responsible for the Group's human resources management and operation. Ms. Xin joined the predecessor of the Group in 1981, focused on administration. She was the Deputy General Manager (human resources management) of Shineway Medical immediately prior to the corporate reorganisation in preparation of the listing of the Company in 2004. Ms. Xin has more than 20 years' experience in business management in the industry with the Group.

LI Huimin (李惠民), aged 45, is an executive director. He graduated from Hebei Party School in 1997 where he majored in economic administration. He is primarily responsible for the marketing and sales of the Group's products and, since joining the Group in 1992, focused on sales and marketing. Immediately prior to the corporate reorganisation in preparation of the listing of the Company in 2004, Mr. Li was the sales and marketing manager of Shineway Medical. He has developed a deep understanding of sales management in the PRC Chinese medicine industry with more than 14 years' experience. Mr. Li is a vice-chairman of Hong Kong Chinese Prepared Medicine Traders Association since 2010.

LEE Ching Ton Brandelyn (李靖形), aged 30, is the daughter of Mr. Li Zhenjiang, the chairman and the chief executive officer of the Company. She has studied in the United Kingdom and Australia, majoring in business administration. Ms. Lee has solid knowledge in finance principles. Furthermore, Ms. Lee has worked in areas relating to corporate development in the Company, thus has accumulated a definite amount of administration and management experience. She has been the Company's Executive Assistant since August 2010. Ms. Lee was appointed as an executive director of the Company on 1 October 2012.

Non-Executive Director

HUNG Randy King Kuen (孔敬權), aged 47, is a fellow Certified Public Accountant in Hong Kong and has extensive experience in corporate finance and investor relation. Mr. Hung is currently an executive director and chief financial officer of China Fiber Optic Network System Group Limited (stock code: 3777), and an independent non-executive director of Zhongyu Gas Holdings Limited (stock code: 3633). Mr. Hung has served as an executive director of the Company from June 2005 to April 2010, and he has also served as an independent non-executive director of Zhongtian International Limited (stock code: 2379) from July 2004 to April 2011. Mr. Hung holds an MBA degree from the University of London, a bachelor's degree of science in accounting and a certificate of programming and data processing from the University of Southern California, a certificate of China Accounting, Finance, Taxation and Law from the Chinese University of Hong Kong and a Hong Kong Securities Institute Specialist Certificate in corporate finance. Mr. Hung is a fellow of the Hong Kong Institute of Certified Public Accountants, a member of the Hong Kong Securities Institute, a vice chairman of the Hong Kong Investor Relations Association and a council member of the Hong Kong Institute of Directors. Mr. Hung was appointed as an non-executive director of the Company on 1 June 2011.

Independent Non-Executive Directors

REN Dequan (任德權), aged 69, is an independent non-executive director. He graduated from East China Chemical Industry Institute (now known as East China Engineering University). He has previously served as the deputy general manager of China Medicinal Herbs Corporation, director of science and technology education of National Medicine Administrative Bureau, general manager of China Pharmaceuticals Corporation, deputy commissioner of National Chinese Medicine Administrative Bureau and deputy commissioner of National Drugs Surveillance Administrative Bureau. From March 2003 to March 2005, he was appointed as assistant commissioner of National Food and Drugs Surveillance Administrative Bureau. In 2005, he has retired and was appointed as the honorary president of the Modern Chinese Medicine International Association. Mr. Ren is currently a non-executive director of Shenzhen Neptunus Interlong Bio-technique Company Limited (stock code: 8329). Mr. Ren was appointed as an independent non-executive director of the Company in 2006.

CHENG Li (程麗), aged 53, is an independent non-executive director. She is a partner of Commerce & Finance Law Office. She has a legal science bachelor's degree and the legal science master's degree from the law department of Japan Special Training University. She also studied in Sino-Japanese Investment Trade Promotion Association. She joined Commerce & Finance Law Office in 1995 and became a partner of Commerce & Finance Law Office in 2002. She is currently a member of Beijing Lawyer Association. Ms. Cheng was appointed as an independent non-executive director of the Company in 2006.

SUN Liutai (孫劉太), aged 49, is an independent non-executive director. He is a Chinese Certified Public Accountant. He was postgraduated in Economic Management Institute of North Western University. Mr. Sun has been working as a partner of Hebei Peking Certified Public Accountants from 2002 to present, during which, in 2003, he was appointed by Hebei Securities and Futures Commission to investigate a company listed on Shenzhen Stock Exchange. Mr. Sun has sound experience in accounting profession and finance. He worked as an assistant manager of general strategic department in China Investment Bank Hebei branch from 1987 to 1992, and worked as an assistant general manager in a Hebei Investment Management Consultancy Company in 1992 to 1995. He then worked as a principal accountant in Hebei Yongzhengde Certified Public Accountants from 1995 to 2002, during which he was engaged in audit of a company listed on the Shanghai Stock Exchange. Mr. Sun was a general committee of Hebei Society of Certified Public Accountants in 2002 to 2008, and was employed as an independent director and audit in-charge of Qinhuangdao Yaohua Glass Co., Ltd (a company listed on the Shanghai Stock Exchange, stock code: 600716) from May 2002 to June 2008. Mr. Sun was appointed as an independent non-executive director of the Company in 2010.

SENIOR MANAGEMENT

CHEN Zhong (陳鍾), aged 46, senior engineer, certified pharmacist, graduated from Hebei Medical University in 1990 with a bachelor's degree in pharmacy. He joined the Group in 1990. From 1990 to 1992, Mr. Chen was responsible for development of new products. After spending two years managing the tablet workshop from 1993 to 1994, he managed the production technology division until 1997 and was then appointed as the chief engineer for production from 1997 to 1999. Since 1999, Mr. Chen has been a Deputy General Manager. Mr. Chen is responsible for the Group's quality control and research and development activities.

WANG Qinli (王欽禮), aged 50, graduated from Henan Chinese Medical Institute with a bachelor's degree in Chinese medicine in 1986. Prior to joining the Group, Mr. Wang spent 10 years, from 1986 to 1996, working in technology and new medicine research at a pharmaceutical manufacturer in Henan Province, the PRC, where he reached the post of Head of New Medicine Research and Head of Technology Department. Mr. Wang joined the Group in 1996 as manager of the research and development department, and then was promoted to Deputy General Manager in 2003, responsible for overseeing the Group's production management and technology development.

LUK Yat Hung (陸一鴻), aged 54, is a fellow member of both Chartered Association of Certified Accountants of the United Kingdom and Hong Kong Institute of Certified Public Accountants with a master degree in business administration with Oklahoma City University and a Hong Kong Securities Institute Specialist Certificate in corporate finance. Mr. Luk joined the Group in 2010, prior to which he has served with a number of international conglomerates and listed groups as chief financial officer and executive director responsible for corporate finance, investor relations and corporate communication. Mr. Luk is responsible for the Group's investor relations and corporate communication.

LEE Bun Ching, Terence (李品正), aged 40, is the Financial Controller of the Group. Mr. Lee is a member of the Hong Kong Institute of Certified Public Accountants and American Institute of Certified Public Accountants. He holds a bachelor degree in Accounting and Financial Analysis and a master degree in Economics and Finance from the University of Warwick in the United Kingdom. Mr. Lee has extensive working experience in the field of auditing, accounting, finance and taxation. He joined the Group in February 2011, prior to which he served as the Group Accounting Controller of a listed company in Hong Kong for over 3 years. Between 1996 and 2007, Mr. Lee worked in a reputable international accounting firm and was a Senior Manager when he left in 2007.

COMPANY SECRETARY

WONG Mei Shan (汪美珊), aged 38, is the Company Secretary and Finance Manager of the Group. Ms. Wong is a Certified Public Accountant of Hong Kong Institute of Certified Public Accountants. She has a bachelor's degree in Accounting from the Hong Kong University of Science and Technology and a bachelor of Laws from the University of London. Ms. Wong joined the Group in 2006 and has extensive working experience in accounting. She has worked in a subsidiary of a listed company in Hong Kong as an accountant for 3 years. Prior to that, she had worked in two international accounting firms for 5 years and was an Assistant Manager when she left in 2002.

The board of directors (the "Board") is pleased to present to the shareholders the annual report and the audited consolidated financial statements of the Company and its subsidiaries (hereinafter collectively referred to as the "Group") for the year ended 31 December 2012.

PRINCIPAL ACTIVITIES

The Company acts as an investment holding company. The principal activities of its subsidiaries are research, development, manufacture and trading of modern Chinese medicines.

RESULTS

The results of the Group for the year ended 31 December 2012, prepared in accordance with the international accounting standards, are set out in the consolidated statement of comprehensive income on page 52 of this annual report.

DIVIDENDS

An interim dividend of RMB11 cents per share, amounting to RMB90,970,000, was paid to the shareholders on 31 October 2012.

The Board now recommends a final dividend of RMB12 cents per share and a special dividend of RMB9 cents per share for the year ended 31 December 2012, to be paid on 20 June 2013, to the shareholders whose names appear on the register of members of the Company on 7 June 2013. The proposed final dividend and special dividend will be voted by shareholders at the annual general meeting (the "AGM") to be held on 31 May 2013.

FINANCIAL HIGHLIGHTS

A summary of the results and assets and liabilities for the last five years, as extracted from the relevant audited financial statements, is set out on page 3 of this annual report. The summary does not form part of the audited financial statements.

PROPERTY, PLANT AND EQUIPMENT

Details of the movement in the property, plant and equipment of the Group during the year are set out in note 12 to the consolidated financial statements.

SHARE CAPITAL AND RESERVES

Details of the movement in share capital and reserves of the Company during the year are set out in the Consolidated Statement of Changes In Equity and also in note 25 to the consolidated financial statements. As at 31 December 2012, the Company's reserves available for distribution to shareholders amounted to RMB866,435,000 (2011: RMB728,931,000). The Company has not issued any shares during the year.

DEBENTURES

The Company has not issued any debentures during the year.

DIRECTORS

The directors of the Company (the "Directors") during the year and up to the date of this report were:

Executive Directors:

Mr. Li Zhenjiang Ms. Wang Zhihua Ms. Xin Yunxia Mr. Li Huimin Ms. Lee Ching Ton Brandelyn (appointed on 1 October 2012)

Non-Executive Director:

Mr. Hung Randy King Kuen

Independent Non-Executive Directors:

Mr. Ren Dequan Ms. Cheng Li Mr. Sun Liutai

The biographical details of the Directors are set out on page 25 to page 28 of this annual report.

Each of Mr. Li Zhenjiang, Ms. Wang Zhihua, Ms. Xin Yunxia, Mr. Li Huimin and Ms. Lee Ching Ton Brandelyn has entered into a service contract with the Company for a term of two years commencing from 1 October 2012. Each service contract will continue thereafter until terminated by not less than three months' notice in writing served by either party on the other.

The non-executive Director and each of the independent non-executive Directors has been appointed for a term of two years. The appointment of each of the independent non-executive Directors is subject to retirement by rotation in accordance with the Company's articles of association (the "Articles of Association").

Other than disclosed above, none of the Directors has entered into or has proposed to enter into any service contract with the Company or any of its subsidiaries which is not expiring or determinable by the employing company within one year without payment of compensation other than statutory compensation.

The Company had received confirmation from each of the independent non-executive Directors of their independence pursuant to Rule 3.13 of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and considered all independent non-executive Directors to be independent.

Pursuant to Article 87(1) of the Articles of Association, Mr. Li Zhenjiang, Mr. Li Huimin and Mr. Ren Dequen will retire from the Board at the forthcoming AGM. Pursuant to Article 86(3) of the Articles of Association, Ms. Lee Ching Ton Brandelyn, will hold office until the forthcoming AGM. The above-mentioned Directors, being eligible for re-election, will offer themselves for re-election at the forthcoming AGM.

Details of Directors' emoluments on a named basis are set out in note 9 to the consolidated financial statements.

DIRECTORS' INTERESTS IN CONTRACTS

Save as disclosed in note 32 to the consolidated financial statements, no contracts of significance to which the Company, any of its holding companies, fellow subsidiaries or any of its subsidiaries was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year ended 31 December 2012.

DIRECTORS' INTERESTS IN SHARES

As at 31 December 2012, the interests and short positions of the Directors and chief executives of the Company and their respective associates in the shares, underlying shares and debentures of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO"), which are required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which are required pursuant to section 352 of the SFO, to be entered in the register referred therein, or which are required, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix 10 to the Listing Rules to be notified to the Company and the Stock Exchange, were as follows:

				Approximate percentage of
	Name of		Number of	shareholding in
Name of director	relevant Company	Capacity	shares	the Company
Li Zhenjiang	Company	Founder of discretionary trust (Note)	540,363,416	65.34%
Lee Ching Ton Brandelyn	Company	Beneficiary owner	835,000	0.10%

Note:

These 540,363,416 shares of the Company ("Shares") are held by Forway Investment Limited ("Forway"). Forway is owned as to 100% by Fiducia Suisse CA, a trust company, in its capacity as the trustee of The Li Family 2004 Trust. The Li Family 2004 Trust is a discretionary trust, the founder (as defined in the SFO) of which is Mr. Li Zhenjiang and the discretionary objects of which are family members of Mr. Li Zhenjiang (excluding Mr. Li Zhenjiang himself). Accordingly, Mr. Li Zhenjiang is deemed to be interested in the 540,363,416 Shares under the SFO.

Save as disclosed above, as at 31 December 2012, none of the Directors or chief executives of the Company or their respective associates had any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

At no time during the year was the Company, its holding companies, fellow subsidiaries or any of its subsidiaries a party to any arrangement to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

SUBSTANTIAL SHAREHOLDERS

Interest in the Company

As at 31 December 2012, interest of every person (not being a director or chief executive of the Company) in the shares and underlying shares in the Company as recorded in the register required to be kept by the Company under Section 336 of the SFO were as follows:

			Approximate
			percentage of
		Number of	shareholding
Name of shareholder	Capacity	shares held	in the Company
Forway	Beneficial owner	540,363,416	65.34%
Fiducia Suisse SA (Notes 1 and 2)	Trustee of discretionary trust	540,363,416	65.34%

Notes:

(1) Interests of Forway and Fiducia Suisse SA in the Shares were duplicated.

(2) The entire issued share capital of Forway is owned by Fiducia Suisse SA in its capacity as the trustee of The Li Family 2004 Trust, a discretionary trust, the founder (as defined in the SFO) of which is Li Zhenjiang and the discretionary objects of which are family members of Li Zhenjiang (excluding Li Zhenjiang himself).

Save as disclosed above, as at 31 December 2012, the Company had not been notified by any persons who (other than the Directors or chief executive of the Company) had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under Divisions 2 and 3 of Part XV of the SFO.

SHARE OPTION SCHEME

The existing share option scheme (the "Scheme"), which was adopted by the Company pursuant to a written resolution of the sole shareholder of the Company passed on 10 November 2004 is for the primary purpose of providing a flexible means of giving incentives to, rewarding, remunerating, compensating and/or providing benefits to the following participants, and for such other purposes as the Board may approve from time to time:

- (i) any executive or non-executive director including any independent non-executive director or any employee (whether full-time or part-time) of any member of the Group;
- (ii) any discretionary object of a discretionary trust established by any substantial shareholder of the Company or any employee, executive or non-executive director of any member of the Group;
- (iii) any consultant, professional and other advisers to any member of the Group;
- (iv) any chief executive or substantial shareholder of any member of the Group;
- (v) any associate of any director, chief executive or substantial shareholder of any member of the Group; and
- (vi) any employee (whether full-time or part-time) of substantial shareholder of any member of the Group to take up Options.

The total number of shares in respect of which options may be granted under the Scheme is 82,700,000 shares, which is equivalent to 10% of the total number of shares of the Company in issue on the date of commencement of dealings in the shares of the Company on the Stock Exchange.

The maximum number of shares of the Company issued and to be issued upon exercise of the options granted to each participant (including both exercised and unexercised options) under the Scheme and any other share option scheme (if any) adopted by the Company in any 12-month period must not exceed 1% of the shares of the Company in issue unless otherwise approved by the Company's shareholders. Where any grant of options to a substantial shareholder, an independent non-executive director, or any of their respective associates (including a discretionary trust whose discretionary objects include a substantial shareholder or an independent non-executive director or a company beneficially owned by any substantial shareholder or independent non-executive director

of the Company) would result in the shares of the Company issued and to be issued upon exercise of all options already granted and to be granted to such person in any 12-month period up to and including the date of the grant:

- (i) representing in aggregate over 0.1% of the shares of the Company in issue; and
- (ii) having an aggregate value, based on the closing price of the shares of the Company as stated in the daily quotations sheets issued by the Stock Exchange on the date of grant in excess of HK\$5 million,

Such grant of option shall be subject to prior approval of the shareholders of the Company who are not connected persons of the Company as defined in the Listing Rules.

An option must be exercised within 10 years from the date of grant or such shorter period as the Board may notify to the grantee.

Option granted must be taken up within 14 days from the date of offer, upon payment of HK\$1 per option. Options may be exercise at any time from the date of grant of the share option to the 10th anniversary of the date of grant. The exercise price is determined by the directors of the Company, and will not be less than the higher of (i) the closing price of the Company's shares on the date of grant, (ii) the average closing price of the shares for the five business days immediately preceding the date of grant; and (iii) the nominal value of the Company's share.

The Scheme has a life of 10 years and will expire on 9 November 2014 unless otherwise terminated in accordance with the terms of the Scheme.

However, no option was granted, exercised, cancelled or lapsed during the year and as at the date of this report since adoption.

PURCHASE, SALE OR REDEMPTION OF SHARES

During the year ended 31 December 2012, the Company or its subsidiaries did not purchase, sell or redeem any shares of the Company.

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Articles of Association although there are no restrictions against such rights under the laws in the Cayman Islands.

MAJOR CUSTOMERS AND SUPPLIERS

The aggregate sales attributable to the largest customer and five largest customers of the Group were 5.4% and 18.2% respectively of the Group's turnover for the year.

The aggregate purchases attributable to the largest supplier and five largest suppliers of the Group were 6.0% and 20.0% respectively of the Group's purchases for the year.

None of the Directors, their associates, or any shareholder (which to the knowledge of the Directors owns more than 5% of the Company's share capital) has any interests in the five largest customers or suppliers of the Group.

CONNECTED TRANSACTIONS

During the year, the Group had the following continuing connected transactions:

Sales to Hebei Shineway Chain Drugstores Co., Ltd ("Shineway Drugstores")

On 31 December 2009, Shineway Pharmaceutical (Hainan) Co., Ltd. ("Hainan Shineway") and Xizang Shineway Pharmaceutical Co., Ltd ("Xizang Shineway"), wholly-owned subsidiaries of the Company, and Shineway Drugstores, a connected person of the Company by virtue of being ultimately controlled by Mr. Li Zhenjiang, an executive Director of the Company, entered into a supply agreement (the "Supply Agreement"). According to the Supply Agreement, the total amount of the annual sales by Hainan Shineway or Xizang Shineway to Shineway Drugstores will not exceed RMB1,000,000 for each of 3 years ending 31 December 2012. For the year ended 31 December 2012, no sales by Hainan Shineway and Xizang Shineway to Shineway Drugstores (2011: RMB768,000).

Tenancy Agreement Between Hainan Shineway and 神威醫藥科技股份有限公司 (Shineway Medical Science & Technology Co., Ltd) ("Shineway Medical")

On 31 December 2009, a tenancy agreement (the "Tenancy Agreement") was entered into between Hainan Shineway and Shineway Medical, a connected person of the Company by virtue of being ultimately controlled by Mr. Li Zhenjiang, an executive Director of the Company. Pursuant to the Tenancy Agreement, Shineway Medical has conditionally leased to Hainan Shineway a portion of office space with an area of approximately 514 square meters in the office owned by Shineway Medical for a period of 2 years from 1 January 2010, and extended for 1 year subsequently. For the year ended 31 December 2012, rental expenditure paid by Hainan Shineway to Shineway Medical amounted to approximately RMB619,000 (2011: RMB619,000).

General Services Agreement Between 神威藥業有限公司 (Shineway Pharmaceutical Co., Limited) ("Shineway Pharmaceutical") and Shineway Medical

On 31 December 2009, Shineway Pharmaceutical, a wholly-owned subsidiary of the Company, and Shineway Medical entered into a general services agreement ("General Services Agreement I"). Pursuant to the General Services Agreement I, Shineway Medical has agreed to provide Shineway Pharmaceutical with property management services, staff benefits facilities and production support services for a term commencing from 1 January 2010 until 31 December 2012. The transaction amount and cap amount of such transaction for the year ended 31 December 2012 are RMB6,802,000 and RMB6,900,000 respectively (2011: RMB6,668,000 and RMB6,700,000 respectively).

Directors' Report

General Services Agreement between Hebei Shineway and Shineway Medical Science & Technology (Lang Fang) Co., Ltd ("Shineway Lang Fang")

On 31 December 2009, Hebei Shineway, a wholly-owned subsidiary of the Company, and Shineway Lang Fang entered into a general services agreement ("General Services Agreement II"). Mr. Li Zhenjiang, an executive Director of the Company, is the controlling shareholder of Shineway Medical, which holds 70% of equity interest in Shineway Lang Fang. Accordingly, Shineway Lang Fang is a connected person of the Company within the meaning of the Listing Rules. Pursuant to the General Services Agreement II, Shineway Lang Fang has agreed to provide Hebei Shineway with property management services, staff benefits facilities and production support services for a term commencing from 1 January 2010 until 31 December 2012. The transaction amount and cap amount of such transaction for the year ended 31 December 2012 are RMB1,747,000 and RMB1,800,000 respectively (2011: RMB1,713,000 and RMB1,750,000 respectively).

The Supply Agreement, Tenancy Agreement and General Services Agreement II involved transaction amounts on annual basis of less than 0.1% for each of the percentage ratios (other than the profits ratio) under Rule 14.07 of the Listing Rules, and hence fall within the de minimise exemption under Rule 14A.33(3) of the Listing Rules. Therefore, the Supply Agreement, Tenancy Agreement and General Services Agreement II are exempt from the reporting, announcement and independent shareholders' approval requirements.

As one of the applicable percentage ratios in respect of the annual caps for the provision of the services to Shineway Pharmaceutical by Shineway Medical contemplated under the General Services Agreement I exceeds 0.1% but is less than 2.5%, being the threshold of the percentage ratios in accordance with Rule 14A.34 of the Listing Rules in effect at the time the General Services Agreement I was entered into, the transactions contemplated under the General Services Agreement I are only subject to the reporting and announcement requirements under Rules 14A.45 to 14A.47 of the Listing Rules and are exempt from the independent shareholders' approval requirements under Rule 14A.48 of the Listing Rules.

The independent non-executive Directors of the Company have reviewed the continuing connected transactions disclosed above and confirmed that:

- (a) the transactions have been entered into by the relevant member of the Group in the ordinary and usual course of business of the Group;
- (b) the transactions have been entered into on arm's length basis and on normal commercial terms (to the extent that there are comparable transactions) or, if there are not sufficient comparable transactions to judge whether they are on normal commercial terms, or terms not less favourable to the Group than terms available to or from (as the case may be) independent third parties; and
- (c) the transactions have been entered into in accordance with the relevant agreements governing them on terms that are fair and reasonable and in the interests of the shareholders of the Company as a whole.

Directors' Report

Pursuant to Rule 14A.38 of the Listing Rules, the Company has engaged the auditor of the Company to perform certain work in accordance with Hong Kong Standard on Assurance Engagements 3000 "Assurance Engagements Other Than Audits or Reviews of Historical Financial Information" and with reference to Practice Note 740 "Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules" issued by the Hong Kong Institute of Certified Public Accountants (the "HKICPA").

The auditor has provided a letter to the Board and confirmed that for the year ended 31 December 2012 the Continuing Connected Transactions (i) have received the approval of the Board; (ii) are in accordance with the pricing policies of the Company for those Transactions that involve provision of goods or services by the Group; (iii) have been entered into in accordance with the relevant agreement governing the transactions and (iv) have not exceeded the cap disclosed in the previous continuing connected transaction announcement on the Stock Exchange by the Company dated 31 December 2009.

The Directors confirm that for the above connected transactions, the Company has complied with the relevant disclosures, reporting and shareholders' approval requirements in Chapter 14A of the Listing Rules. The above connected transactions are also reported in note 32 to the consolidated financial statements of this Annual Report as Related Party Transactions.

MANAGEMENT CONTRACTS

No contracts concerning the management and administration of the whole or any substantial part of the business of the Company were entered into or existed during the year ended 31 December 2012.

EMOLUMENT POLICY

The emolument policy of the employees of the Group is set up by the Remuneration Committee on the basis of their merit, qualification and competence.

The emoluments of the Directors are decided by the Remuneration Committee, having regard to the Company's operating results, individual performance and comparable market statistics.

The Directors' fees, basic salaries, housing allowances, other allowances and benefits in kind are disclosed in note 9 to the consolidated financial statements.

The contributions to pension schemes for Directors for the financial year are disclosed in note 9 to the consolidated financial statements.

Directors' Report

Pursuant to the Directors' service contracts with the Company, all executive Directors may be entitled to a discretionary bonus to be determined by the Board (or its duly appointed remuneration committee) at its absolute discretion having regard to the performance of the Group, provided that the aggregate amount of the bonus payable to those Directors in respect of any financial year shall not exceed 5% of the audited consolidated net profit after taxation but before extraordinary items of the Company for the relevant financial year.

There was no compensation paid during the financial year ended 31 December 2012 or receivable by Directors or past Directors for the loss of office as a director of any member of the Group or of any other office in connection with the management of the affairs of any member of the Group distinguishing between contractual and other payments.

PENSION SCHEMES

The pension schemes of the Group are primarily in the form of contributions to the Hong Kong Mandatory Provident Fund and China's statutory public welfare fund.

SUFFICIENCY OF PUBLIC FLOAT

Based on information that is publicly available to the Company and within the knowledge of the Directors as at the date of this report, the Company has maintained a sufficient public float throughout the year of 2012 as required under the Listing Rules.

CHARITABLE DONATIONS

During the year, the Group has not made charitable donations (2011: Nil).

AUDITOR

A resolution will be submitted to the AGM to re-appoint Messrs. Deloitte Touche Tohmatsu as auditor of the Company.

On behalf of the Board

LI ZHENJIANG CHAIRMAN OF THE BOARD

Hong Kong, 26 March 2013

Dear Shareholders,

The Group is firmly committed to statutory and regulatory corporate governance standards and adhere to the principles of corporate governance emphasising transparency, independence, accountability, responsibility and fairness.

The Board believes that good corporate governance practices are essential elements in guiding the growth and management of the business of the Group. Therefore the Board reviews its corporate governance practices from time to time to ensure that they protect the shareholders' interest, comply with legal and professional standards and reflect the latest local and international circumstances and development. The Board will continue to commit itself to achieving a high quality of corporate governance.

CORPORATE GOVERNANCE CODE

The Company has, throughout the year ended 31 December 2012 and up to the date of publication of this annual report, applied and complied with the principles in the Corporate Governance Code (the "Code") set out in Appendix 14 to the Listing Rules, except for code provision A.2.1 as described below.

DIRECTORS' SECURITIES TRANSACTIONS

The Company has adopted the full set of the Model Code as set out in Appendix 10 to the Listing Rules as the code of conduct for securities transactions by Directors. The prohibitions on securities dealing and disclosure requirements in the Model Code apply to specified individuals including the Group's senior management and also persons who are privy to price sensitive information of the Group. The interests in the Company's securities held by the Directors as at 31 December 2012 as set out on page 31 and the extent of applications of the Model Code are disclosed in this Corporate Governance Report. Based on specific inquiries made by the company secretary of the Company, all Directors confirmed that they had complied with the Model Code regarding directors' securities transactions during the year and up to the date of publication of the Annual Report.

THE BOARD OF DIRECTORS

The Board represents shareholders in overseeing the Group's business. The Directors recognise their responsibilities to enhance shareholders' value and to conduct themselves in accordance with their duty of care and loyalty.

As at the date of this report, the Board comprises five executive Directors, one non-executive Director and three independent non-executive Directors. Pursuant to the requirements of the Listing Rules, the Company has received written confirmation from each independent non-executive Director of his/her independence during his/her period of service during the year. The Group considered them to be independent. The names of the Directors and their respective biographies are set out on pages 25 to 28 of this annual report. The information is also published on the Company's websites.

The Company had arranged for appropriate liability insurance for the directors and officers of the Group for indemnifying their liabilities arising from corporate activities.

Every newly appointed director will be given an induction so as to ensure that he/she has appropriate understanding of the Group's business and of his/her duties and responsibilities under the Listing Rules and the relevant statutory and regulatory requirements. The directors may request the Company to provide independent professional advice at the Company's expense to discharge his/her duties to the Company. Directors' training is an ongoing process. During the year, the Company had provided to the directors regular updates and presentations on changes and developments to the Group's business and to the legislative regulatory environments in which the Group operates. All directors are also encouraged to attend relevant training courses at the Company's expense. All directors are required to provide the Company with their record of training they received during the year ended 31 December 2012.

During the year ended 31 December 2012, the Board has reviewed and monitored the training and continuous professional development of directors and senior management. The Board has also reviewed and ensured compliance of the relevant legal and regulatory requirements, the code of conducts, the Code and the disclosure in the Corporate Governance Report.

The Board oversees the Group's strategic development, and determines the objectives, strategies and policies of the Group. The Board also monitors and controls operating and financial performance in pursuit of the Group's strategic objectives. All Board members have access to appropriate business documents and information about the Group on a timely basis. All Directors and board committees have access to external legal counsel and other professionals for independent advice at the Group's expense if they require it.

Three board committees, namely, the audit committee (the "Audit Committee"), the remuneration committee (the "Remuneration Committee") and the nomination committee (the "Nomination Committee") (established in March 2012), have been established to oversee particular aspects of the Group's affairs. The Board has delegated the day-to-day management and operations of the Group's businesses to the management of the Company and its subsidiaries respectively. Major corporate matters that are specifically delegated by the Board to the management include the preparation of financial statements for board approval before publishing, execution of business strategies and initiatives adopted by the Board, implementation of adequate systems of internal controls and risk management procedures, and compliance with relevant statutory requirements, rules and regulations.

The Board had met four times this year to review the financial performance of the Group, major issues (whether or not required by the Listing Rules) and also on other occasions when Board decisions were required. The views of independent non-executive Directors were actively solicited by the Group if they were unable to attend meetings of the Board.

The major issues which were brought before the Board for their decisions during the year include:

- 1. formulation of operational strategies and review of its financial performance and results and the internal control system;
- 2. policies relating to key business and financial objectives of the Group;
- 3. proposals related to potential acquisitions, investments, or any significant capital expenditures; and
- 4. the declaration of interim dividend and recommendation to shareholders on final dividend.

From April 2012 onwards, all Directors have been provided, on a monthly basis, with the Group's management information updates to give them aware of the Group's affairs and facilitates them to discharge their duties under the relevant requirements of the Listing Rules.

The Board held 4 Board meetings and one annual general meeting ("AGM") in 2012. Details of the attendance of the Board are as follows:

	Attended/Held	
	Board Meeting	AGM
Executive Directors		
Mr. Li Zhenjiang (Chairman of the Board)	4/4	1/1
Ms. Wang Zhihua	4/4	1/1
Ms. Xin Yunxia	4/4	1/1
Mr. Li Huimin	4/4	1/1
Ms. Lee Ching Ton Brandelyn (appointed on 1 October 2012)	_	_
Non-executive Director		
Mr. Hung Randy King Kuen	4/4	1/1
Independent Non-executive Directors		
Mr. Ren Dequan	4/4	1/1
Ms. Cheng Li	4/4	1/1
Mr. Sun Liutai	4/4	1/1

The Directors acknowledged that they are responsible for the preparation of the accounts which give a true and fair view of the affairs of the Group. The auditor is responsible to form an independent opinion, based on their audits, on the Group's financial statements and express their opinions.

The Board has the overall responsibility to ensure that the Company maintains sound and effective internal controls to safeguard the shareholders' investments and the Company's assets. The internal audit department has been conducting regular review of the system's effectiveness and reports to the Directors and the audit committee on its material findings.

CHAIRMAN AND CHIEF EXECUTIVE OFFICER

The Code provision A.2.1 of the Code stipulates that the roles of chairman of the board (the "Chairman") and chief executive officer should be separate and should not be performed by the same individual. The division of responsibilities between the Chairman and chief executive officer should be clearly established and set out in writing. The Company does not use the title "Chief Executive Officer". The duty of chief executive officer has been assumed by the president of the Company (the "President").

Mr. Li Zhenjiang has been both the Chairman and President of the Company. His responsibilities are clearly set out in writing and approved by the Board. Given the Group's current stage of development, the Board considers that vesting the roles of Chairman and President in the same person facilitates the execution of the Group's business strategies and maximizes effectiveness of its operations. The Board shall nevertheless review the structure from time to time and shall consider any appropriate adjustments should new circumstances arise.

CONTINUOUS PROFESSIONAL DEVELOPMENT

Pursuant to code provision A.6.5 of the Code, which has come into effect from 1 April 2012, all directors should participate in continuous professional development to develop and refresh their knowledge and skills. This is to ensure that their contribution to the Board remains informed and relevant. During the year ended 31 December 2012, all directors have participated in continuous professional development by attending training courses and/or referring materials on the topics related to corporate governance and regulations:

Executive Directors

Mr. Li Zhenjiang	Attending training course
Ms. Wang Zhihua	Self-study of relevant materials
Ms. Xin Yunxia	Attending training course
Mr. Li Huimin	Attending training course
Ms. Lee Ching Ton Brandelyn	Attending training course

Non-executive Director

Mr. Hung Randy King Kuen

Attending training course

Independent Non-executive Directors

Mr. Ren Dequan	Attending training course
Ms. Cheng Li	Attending training course
Mr. Sun Liutai	Self-study of relevant materials

NON-EXECUTIVE DIRECTORS

The non-executive Director has entered into an appointment letter with the Company for a term of two years or till retirement by rotation in accordance with the Articles of Association, if earlier.

REMUNERATION OF DIRECTORS

The Company established a remuneration committee on 10 November 2004 with written terms of reference as disclosed on the Company's websites and the website of the Stock Exchange. The primary duties of the Remuneration Committee include the following:

- I. To make recommendation to the Board on (a) the Company's policy and structure for all remuneration of Directors and senior management, and (b) the Company's establishment of a formal and transparent procedure for developing policy on such remuneration;
- 2. To determine the specific remuneration packages of all executive Directors, and senior management, including benefits in kind, pension rights, and compensation payments (including any compensation for loss or termination of office or appointment);
- 3. To make recommendation to the Board on the remuneration of independent non-executive Directors;
- 4. To have due consideration of all relevant factors such as salaries paid by comparable companies, time commitment and responsibilities of the Directors, employment conditions elsewhere in the Group and desirability of performance-based remuneration;
- 5. To review and approve performance-based remuneration by reference to corporate goals and objectives resolved by the Board from time to time;
- 6. To review and approve the compensation payable to executive Directors and senior management in connection with any loss or termination of their office or appointment to ensure that such compensation is determined in accordance with relevant contractual terms and that such compensation is otherwise fair and not excessive for the Company;
- 7. To review and approve the compensation arrangements relating to dismissal or removal of Directors for misconduct to ensure that such arrangements are determined in accordance with relevant contractual terms and that any compensation payment is otherwise reasonable and appropriate;
- 8. To ensure that no Director or any of his associates is involved in deciding his own remuneration.

As at the date of this report, the members of the Remuneration Committee comprises two independent non-executive Directors, Ms. Cheng Li and Mr. Sun Liutai, and executive Director Ms. Xin Yunxia. Ms. Cheng Li is the chairman of the Remuneration Committee. The Remuneration Committee met four times during the year to review the long term incentive scheme of the Group, and assess the performance of executive Directors.

Individual attendance of each Remuneration Committee member is as follows:

	Attendance
Ms. Cheng Li (Chairman)	4/4
Mr. Sun Liutai	4/4
Ms. Xin Yunxia	4/4

The emolument policy of the employees of the Group was set up by the Remuneration Committee on the basis of their merit, qualification and competence.

The emoluments of the Directors are determined by the Remuneration Committee, having regard to the Group's operating results, individual performance and comparable market statistics.

Further details on the emolument policy and basis of determining the emolument payable to the Directors are disclosed on page 37 to 38 of this annual report.

The Group's share option scheme as described on page 33 to 34 of this annual report is adopted as the Group's long term incentive scheme.

NOMINATION COMMITTEE

The Company established the Nomination Committee in March 2012, the members of Nomination Committee comprises Chairman Mr. Li Zhenjiang and two independent non-executive Directors, Mr. Ren Dequan and Mr. Sun Liutai. Mr. Li Zhenjiang is the chairman of the Nomination Committee. The Nomination Committee was established with written terms of reference in compliance with the Code. The Nomination Committee is responsible for reviewing the structure, size and composition of the Board, making recommendation to the Board on selection of candidates for directorships, appointment, reappointment of Directors and Board succession and assessing the independence of independent non-executive Directors. The Board is responsible for considering and to assessing candidates for directorships on the Board based on their characters, qualifications and experience appropriate for the businesses of the Group. Prior to that the nomination and appointment of directors are directly considered and assessed by the executive Directors.

During the year and up to the date of this report, the Nomination Committee had considered and accepted the nomination of an executive Director who joined the Group on 1 October 2012.

All Directors are appointed for a fixed term. The Articles of Association required that one-third of the Directors (including executive and non-executive Directors) shall retire each year. The Directors to retire each year shall be those appointed by the Board during the year and those who have been longest in office since their election or re-election. A retiring Director is eligible for re-election.

INTERNAL CONTROL

The Board is responsible for ensuring that sound and effective internal control systems are maintained within the Group. The Company and its subsidiaries have adopted a set of internal control procedures and policies to safeguard the assets, to ensure proper maintenance of accounting records and reliability of financial reporting, and to ensure compliance with relevant legislation and regulations. The internal control systems are designed to ensure that the financial and operational functions, compliance control, material control, asset management and risk management functions are in place and functioning effectively.

The Board and the Audit Committee have delegated the Group's internal audit department to conduct periodic review of the effectiveness of the internal control systems of the Company and its subsidiaries, covering all material controls, including financial, operational and compliance controls as well as risk management functions.

Based on the assessments made by the Group's internal audit department, the Board considered that the internal control systems of the Company and its subsidiaries are effective and the Audit Committee has found no material deficiencies on the internal control based on the assessments made by the Group's internal audit department.

AUDITOR'S REMUNERATION

Since 2004, Deloitte Touche Tohmatsu has been appointed as the Group's external auditor by shareholders annually. During the year, the fees charged to the accounts of the Company and its subsidiaries for Deloitte Touche Tohmatsu's statutory audit services amounted to HK\$1,860,000 (2011: HK\$1,860,000), and in addition to a total of HK\$410,000 (2011: HK\$410,000) for other services, including the review of interim financial statements.

AUDIT COMMITTEE

As at the date of this report, the Audit Committee comprise Mr. Sun Liutai, Mr. Ren Dequan and Ms. Cheng Li. All of the members of the Audit Committee are Independent non-executive Directors. Mr. Sun Liutai, who has appropriate professional qualifications or accounting or related financial management expertise, is the chairman of the Audit Committee. No member of this committee is a member of the former or external auditor of the Company. The committee members possess diversified industry experience.

The Audit Committee's primary responsibilities include overseeing the relationship with the Company's external auditor, review of financial information of the Group, and oversight of the Group's financial reporting system, internal control procedures and risk management. The Company has adopted terms of reference of the audit committee which complies with the provisions of the Code. The terms of reference of the Audit Committee is available on the Company's website and the website of the Stock Exchange.

Individual attendance of each Audit Committee member during the year ended 31 December 2012 was as follows:

	Attendance
Mr. Sun Liutai (Chairman)	4/4
Mr. Ren Dequan	4/4
Ms. Cheng Li	4/4

The Audit Committee met on four occasions during the year ended 31 December 2012 and the report on the work performed by the Audit Committee can be found on page 49 of this annual report.

ACCOUNTABILITY AND AUDIT

The Directors acknowledged their responsibility to present a balanced, clear and understandable assessment of the Group's performance, position and prospects in the consolidated financial statements of the annual and interim reports. They are not aware of material uncertainties relating to events or conditions that might cast significant doubt upon the Company's ability to continue as a going concern.

The statement by the auditor of the Company regarding their reporting responsibilities on the financial statements of the group is set out in the Independent Auditor's Report on pages 50 to 51.

In preparing the financial statements for the year ended 31 December 2012, the Directors have adopted appropriate accounting policies and applied them consistently, and have made judgments and estimates that are prudent and reasonable.

The Group has announced its annual and interim results in a timely manner within the limits of three months and two months respectively after the end of the relevant financial periods, as laid down in the Listing Rules.

COMMUNICATION WITH SHAREHOLDERS

The Group attaches great priority to communication with shareholders and investors. Since our listing on the Main Board of the Stock Exchange in December 2004, the Group has regularly met with investors to increase corporate transparency. During the year ended 31 December 2012, the Group met and/or held telephone conferences with a number of investors and participated in institutional investor conferences. We held a number of site visits for investors.

To foster effective communication, the Company provides extensive information in its annual report, interim report, press releases and also disseminates information relating to the Group and its business electronically through its website and the website of the Stock Exchange.

Since October 2005, to enable the shareholders to better evaluate the operations and performance of the Group, the Group has been announcing quarterly financial Information on turnover in due course after the relevant period ended.

The Company regards the annual general meeting as an important event as it provides an important opportunity for direct communication between the Board and shareholders. Directors and senior management will make an effort to attend the annual general meeting. The chairman of the Board, as well as the respective chairmen of the Audit Committee and the Remuneration Committee and external auditor will usually be available during the annual general meeting to address shareholders' queries. All shareholders are given at least 20 clear business days' notice of the annual general meeting and they are encouraged to attend the annual general meeting and other shareholders' meetings. Questions from the shareholders at such meetings are encouraged and welcomed.

SHAREHOLDERS' RIGHTS

(i) **Procedures for members to convene an extraordinary general meeting ("EGM")**

Shareholders holding at the date of deposit of the requisition not less than one-tenth of the paid-up capital of the Company carrying the right of voting at general meetings of the Company shall at all times have the right, by written requisition sent to the Board or the Company Secretary of the Company, to require a EGM to be called by the Board for the transaction of any business specified in such requisition; and such meeting shall be held within two months after the deposit of such requisition. If within twenty-one days of such deposit the Board fails to proceed to convene such meeting, the Shareholders concerned themselves may do so in the same manner.

If the requisition is in order, the Company Secretary will ask the Board to convene a EGM by serving sufficient notice in accordance with the statutory requirements to all the registered Members. On the contrary, if the requisition is invalid, the Shareholders concerned will be advised of this outcome and accordingly, a EGM will not be convened as requested.

The notice period to be given to all the registered Members for consideration of the proposal raised by the shareholders concerned at a EGM varies according to the nature of the proposal, as follows:

- not less than twenty-one clear days' notice in writing if the proposal constitutes a special resolution of the Company; and
- not less than fourteen clear days' notice in writing if the proposal constitutes an ordinary resolution of the Company.

(ii) Procedures for a member to propose a person for election as a director

According to our articles of association, any shareholder(s) duly qualified to attend and vote at general meetings of the Company wish(es) to propose a person (other than himself) for election as a director (the "Candidate") at a general meeting of the Company, the following documents must be lodged at the head office or registered office: (i) a written notice of such proposed duly signed by the shareholder(s) concerned; and (ii) a written consent duly signed by the Candidate indicating his/her willingness to be elected. The period for lodgment of the above documents (being a period of at least seven days) shall commence no earlier than the day after the despatch of the notice of the meeting appointed for such election and end no later than seven days prior to the date of such meeting.

(iii) Procedures for putting forward proposals at a general meeting

Section 115A of the Companies Ordinance provides that (i) shareholder(s) representing not less than onefortieth of the total voting rights of all shareholders of the Company or (ii) not less than 50 shareholders holding the shares in the Company on which there has been paid up an average sum of not less than HK\$2,000 per shareholder can put forward proposals for consideration at a general meeting of the Company by depositing a requisition in writing signed by the relevant shareholder(s) on the registered office.

CODE OF CONDUCT

Employees of the Group have maintained high levels of ethical standards. The Group published an employee handbook, setting out standards of professional and ethical conduct for all employees of the Group. Trainings on the contents of the employee handbook have been held regularly. The employees at all levels are expected to act in an honest, diligent and responsible manner.

Audit Committee Report

Dear Shareholders,

The Audit Committee formally met four times during the year and other informal meetings were conducted as and when necessary. These meetings were held together with senior management and external auditor as and when necessary, to consider the external auditor's proposed audit fees, their independence and scope of the audit; review the internal control and risk management systems; review the interim and annual financial statements, particularly judgmental areas, accounting principles and practice adopted by the Group; review the external auditor's management letter and management's response; and review the Group's adherence to the Corporate Governance Code as set out at Appendix 14 to the Listing Rules.

The Audit Committee recommended the Board to re-appoint Deloitte Touche Tohmatsu as external auditor for the fiscal year 2013 and recommended to approve the interim and annual reports.

MEMBERS OF THE AUDIT COMMITTEE

Mr. Sun Liutai *(Chairman)* Mr. Ren Dequan Ms. Cheng Li

26 March 2013

Independent Auditor's Report



TO THE MEMBERS OF CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

中國神威藥業集團有限公司 (incorporated in the Cayman Islands with limited liability)

We have audited the consolidated financial statements of China Shineway Pharmaceutical Group Limited (the "Company") and its subsidiaries (collectively referred to as the "Group") set out on pages 52 to 100, which comprise the consolidated statement of financial position as at 31 December 2012, and the consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

DIRECTORS' RESPONSIBILITY FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with International Financial Reporting Standards and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on these consolidated financial statements based on our audit and to report our opinion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. We conducted our audit in accordance with Hong Kong Standards on Auditing issued by the Hong Kong Institute of Certified Public Accountants. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

Independent Auditor's Report

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the consolidated financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

OPINION

In our opinion, the consolidated financial statements give a true and fair view of the Group's state of affairs as at 31 December 2012, and of its profit and cash flows for the year then ended in accordance with International Financial Reporting Standards and have been properly prepared in accordance with the disclosure requirements of the Hong Kong Companies Ordinance.

Deloitte Touche Tohmatsu

Certified Public Accountants Hong Kong 26 March 2013

Consolidated Statement of Comprehensive Income For the year ended 31 December 2012

		2012	2011
	NOTES	RMB'000	RMB'000
Turnover	5	2,132,249	1,984,542
Cost of sales		(740,303)	(682,459)
Gross profit		1,391,946	1,302,083
Other income		76,289	123,760
Investment income	6	80,007	68,523
Net exchange loss		(4,733)	(2,837)
Distribution costs		(423,258)	(255,398)
Administrative expenses		(252,762)	(229,244)
Research and development costs		(68,046)	(57,387)
Share of profit of an associate		293	
Profit before taxation		799,736	949,500
Taxation	7	(152,081)	(193,924)
Profit and total comprehensive income for the year	8	647,655	755,576
Profit and total comprehensive income			
for the year attributable to:			
Owners of the Company		647,704	755,600
Non-controlling interests		(49)	(24)
		647,655	755,576
		,	
Earnings per share – basic	11	78 cents	91 cents
carrings per share basic		70 cents	JT CONUS

Consolidated Statement of Financial Position

As at 31 December 2012

		2012	2011
	NOTES	RMB'000	RMB'000
Non-current assets			
Property, plant and equipment	12	1,398,248	1,108,304
Prepaid lease payments	13	148,005	150,449
Intangible assets	14	738	1,430
Interest in an associate	15	17,013	-
Goodwill	16	91,663	91,663
Deferred tax assets	17	25,924	25,825
		1,681,591	1,377,671
Current assets			
Inventories	18	203,965	282,772
Trade receivables	19	203,385	13,397
Bills receivables	19	501,233	404,320
Prepayments, deposits and other receivables		103,610	98,163
Pledged bank deposits	20	19,860	27,839
Bank balances and cash	21	2,212,391	2,172,812
		3,061,444	2,999,303
Current liabilities		0,001,111	2,000,000
Trade payables	22	255,071	261,950
Bills payables	22	19,731	201,930
Other payables and accrued expenses		328,923	303,491
Amount due to a related company	23	9,009	9,009
Deferred income	23	4,099	3,100
Tax liabilities	21	38,234	40,890
			646,279
		655,067	040,279
Net current assets		2,406,377	2,353,024
Total assets less current liabilities		4,087,968	3,730,695
Non-current liabilities			
Deferred tax liabilities	17	1,014	1,076
Deferred income	24	90,336	74,666
		91,350	75,742
		3,996,618	3,654,953

Consolidated Statement of Financial Position

As at 31 December 2012

		2012	2011
	NOTE	RMB'000	RMB'000
Capital and reserves			
Share capital	25	87,662	87,662
Reserves		3,908,429	3,566,715
Equity attributable to owners of the Company		3,996,091	3,654,377
Non-controlling interests		527	576
		3,996,618	3,654,953

The consolidated financial statements on pages 52 to 100 were approved and authorised for issue by the Board of Directors on 26 March 2013 and are signed on its behalf by:

LI ZHENJIANG DIRECTOR **WANG ZHIHUA** DIRECTOR

Consolidated Statement of Changes In Equity For the year ended 31 December 2012

				Statutory surplus	Discretionary surplus		Total equity attributable to	Non-	
	Share	Share	Merger	reserve	reserve	Accumulated	owners of	controlling	Total
	capital	premium	reserve	fund	fund	profits	the Company	interests	equity
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
			(Note a)	(Note b)	(Note b)				
At 1 January 2011	87,662	982,408	83,758	374,944	154,760	1,546,045	3,229,577	_	3,229,577
Profit and total comprehensive									
income for the year	-	-	-	-	-	755,600	755,600	(24)	755,576
Capital contribution from									
non-controlling interests									
of a subsidiary	-	-	-	-	-	-	-	600	600
Transfers	-	-	-	22,834	-	(22,834)	-	-	-
Dividends paid (Note 10)	-	-	-	-	-	(330,800)	(330,800)	-	(330,800)
At 31 December 2011	87,662	982,408	83,758	397,778	154,760	1,948,011	3,654,377	576	3,654,953
Profit and total comprehensive	,	,	,	,	,	, ,	, ,		, ,
income for the year	-	_	-	-	-	647,704	647,704	(49)	647,655
Transfers	-	-	-	32,388	-	(32,388)	-	-	-
Dividends paid (Note 10)	-	(215,020)	_	-	_	(90,970)	(305,990)	-	(305,990)
At 31 December 2012	87,662	767,388	83,758	430,166	154,760	2,472,357	3,996,091	527	3,996,618

Consolidated Statement of Changes In Equity

For the year ended 31 December 2012

Notes:

- (a) Merger reserve of the Group represents the difference between the net asset value of the subsidiaries and the nominal amount of the Company's shares which were issued as consideration for the subsidiaries at the time of the group reorganisation in preparation for the listing of the Company's shares.
- (b) Statutory surplus reserve fund and discretionary surplus reserve fund are appropriated each year by certain subsidiaries on the basis of 10% of the profit after taxation as determined by the board of directors of the relevant subsidiaries and at the rate decided by the shareholders annually, respectively, in accordance with the Articles of Associations ("Articles") of the relevant subsidiaries. According to the provision of the Articles, in normal circumstances, this reserve should only be used for making up losses, capitalisation into capital and expansion of production and operation.

Consolidated Statement of Cash Flows

For the year ended 31 December 2012

	2012	2011
	RMB'000	RMB'000
Operating activities		
Profit before taxation	799,736	949,500
Adjustments for:		
Amortisation of intangible assets	692	735
Depreciation of property, plant and equipment	77,681	64,948
Loss on disposal of property, plant and equipment	39	105
Interest income	(31,553)	(41,114)
Investment income from debt related products	(6,070)	(3,135)
Investment income from short-term debt-related products	(42,384)	(24,274)
Share of profit of an associate	(293)	-
Amortisation of prepaid lease payments	3,629	3,608
Government grant recognised as other income	(4,120)	(9,555)
Reversal of bad and doubtful debts	-	(1,963)
Net exchange loss	-	2,837
Operating cash flows before movements in working capital	797,357	941,692
Decrease (increase) in inventories	78,807	(90,847)
Increase in trade and bills receivables	(103,901)	(145,037)
Decrease in prepayments, deposits and other receivables	7,863	1,751
(Decrease) increase in trade and bills payables	(14,987)	86,961
Increase (decrease) in other payables and accrued expenses	25,432	(84,216)
Decrease in amount due to a related company	-	(11)
Cash generated from operations	790,571	710,293
People's Republic of China Enterprise Income Tax paid	(154,898)	(225,231)
Net cash generated from operating activities	635,673	485,062

Consolidated Statement of Cash Flows For the year ended 31 December 2012

Proceeds from redemption of debt-related products274,090154,755Net proceeds from short-term debt-related products42,38424,272Withdrawal of pledged bank deposits20,78910,055Interest received18,27035,309Purchase of property, plant and equipment(367,666)(396,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)-Payment for land use rights(11,210)-Settlement of consideration payable for acquisition-(11,660)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Lifect of exchange rate changes of cash and cash equivalents-(2,835)		2012	2011
Proceeds from redemption of debt-related products274,090154,755Net proceeds from short-term debt-related products42,38424,272Withdrawal of pledged bank deposits27,83935,068Government grants received20,78910,055Interest received18,27035,309Purchase of property, plant and equipment(367,666)(396,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(16,720)-Acquisition of investment in an associate(16,720)-Payment for land use rights(11,210)-Settlement of consideration payable for acquisition of subsidiaries(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary-600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at tend of the year,-(2,835)		RMB'000	RMB'000
Net proceeds from short-term debt-related products42,38424,272Withdrawal of pledged bank deposits27,83935,068Government grants received20,78910,055Interest received18,27035,309Purchase of property, plant and equipment(367,666)(396,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)-Payment for land use rights(11,210)-Settlement of consideration payable for acquisition-(11,660)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Dividends paid(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at end of the year,-(2,835)	Investing activities		
Withdrawal of pledged bank deposits27,83935,068Government grants received20,78910,055Interest received18,27035,309Purchase of property, plant and equipment(367,666)(396,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)-Payment for land use rights(11,210)-Settlement of consideration payable for acquisition(11,660)(328,236)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Dividends paid(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at end of the year,-(2,835)	Proceeds from redemption of debt-related products	274,090	154,755
Government grants received20,78910,055Interest received18,27035,309Purchase of property, plant and equipment(367,666)(396,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)-Payment for land use rights(1,210)-Settlement of consideration payable for acquisition(11,660)-of subsidiaries(290,104)(328,236)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Dividends paid(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at end of the year,-(2,835)	Net proceeds from short-term debt-related products	42,384	24,272
Interest received18,27035,309Purchase of property, plant and equipment(367,666)(396,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)–Payment for land use rights(1,210)–Settlement of consideration payable for acquisition–(11,660)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Dividends paid(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year–(2,835)Cash and cash equivalents at end of the year,–(2,835)	Withdrawal of pledged bank deposits	27,839	35,068
Purchase of property, plant and equipment(367,666)(39,578)Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)-Payment for land use rights(1,210)-Settlement of consideration payable for acquisition(11,660)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary-600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at end of the year,-(2,835)	Government grants received	20,789	10,055
Acquisition of debt-related products(268,020)(151,620)Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)–Payment for land use rights(1,210)–Settlement of consideration payable for acquisition(11,210)–of subsidiaries(290,104)(328,236)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Dividends paid(305,990)(330,200)Capital contribution from non-controlling interests in a subsidiary–600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year–(2,835)Cash and cash equivalents at end of the year,–(2,835)	Interest received	18,270	35,309
Placement of pledged bank deposits(19,860)(27,839)Acquisition of investment in an associate(16,720)-Payment for land use rights(1,210)-Settlement of consideration payable for acquisition(11,660)of subsidiaries-(11,660)Net cash used in investing activities(290,104)(328,236)Financing activities(305,990)(330,800)Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary-600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at end of the year,(2,835)	Purchase of property, plant and equipment	(367,666)	(396,578)
Acquisition of investment in an associate(16,720)Payment for land use rights(1,210)Settlement of consideration payable for acquisition(1,210)of subsidiaries(11,660)Net cash used in investing activities(290,104)Financing activities(305,990)Dividends paid(305,990)Capital contribution from non-controlling interests in a subsidiary(305,990)Net cash used in financing activities(305,990)Net cash used in financing activities(305,990)Net cash used in financing activities(305,990)Net increase (decrease) in cash and cash equivalents for the year39,579Cash and cash equivalents at beginning of the year2,172,812Effect of exchange rate changes of cash and cash equivalents(2,835)Cash and cash equivalents at end of the year,(2,835)	Acquisition of debt-related products	(268,020)	(151,620)
Payment for land use rights(1,210)Settlement of consideration payable for acquisition of subsidiaries(1,210)Net cash used in investing activities(290,104)Dividends paid(305,990)Capital contribution from non-controlling interests in a subsidiary(305,990)Net cash used in financing activities(305,990)Net increase (decrease) in cash and cash equivalents for the year39,579Cash and cash equivalents at beginning of the year(2,712,812)Effect of exchange rate changes of cash and cash equivalents(2,835)Cash and cash equivalents at end of the year,(2,835)	Placement of pledged bank deposits	(19,860)	(27,839)
Settlement of consideration payable for acquisition of subsidiaries(11,660)Net cash used in investing activities(290,104)(328,236)Financing activities Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary-600Net cash used in financing activities(305,990)(330,200)Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents-(2,835)Cash and cash equivalents at end of the year,-(2,835)	Acquisition of investment in an associate	(16,720)	-
of subsidiaries(11,660)Net cash used in investing activities(290,104)Financing activities(305,990)Dividends paid(305,990)Capital contribution from non-controlling interests in a subsidiary(305,990)Net cash used in financing activities(305,990)Net cash used in financing activities(305,990)Net increase (decrease) in cash and cash equivalents for the year39,579Cash and cash equivalents at beginning of the year2,172,812Effect of exchange rate changes of cash and cash equivalents-Cash and cash equivalents at end of the year,-	Payment for land use rights	(1,210)	-
Net cash used in investing activities (290,104) (328,236) Financing activities (305,990) (330,800) Dividends paid (305,990) (330,800) Capital contribution from non-controlling interests in a subsidiary – 600 Net cash used in financing activities (305,990) (330,200) Net increase (decrease) in cash and cash equivalents for the year 39,579 (173,374) Cash and cash equivalents at beginning of the year 2,172,812 2,349,021 Effect of exchange rate changes of cash and cash equivalents – (2,835) Cash and cash equivalents at end of the year, – (2,835)	Settlement of consideration payable for acquisition		
Financing activities(305,990)(330,800)Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary–600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,–(2,835)	of subsidiaries	_	(11,660)
Financing activities(305,990)(330,800)Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary–600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,–(2,835)			
Financing activities(305,990)(330,800)Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary–600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,–(2,835)	Net cash used in investing activities	(290.104)	(328.236)
Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary—600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents—(2,835)Cash and cash equivalents at end of the year,——		((0 = 0) = 0 0)
Dividends paid(305,990)(330,800)Capital contribution from non-controlling interests in a subsidiary—600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents—(2,835)Cash and cash equivalents at end of the year,——	Einancing activities		
Capital contribution from non-controlling interests in a subsidiary—600Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents—(2,835)Cash and cash equivalents at end of the year,——		(305 990)	(330,800)
Net cash used in financing activities(305,990)(330,200)Net increase (decrease) in cash and cash equivalents for the year39,579(173,374)Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,		(303,330)	
Net increase (decrease) in cash and cash equivalents for the year 39,579 (173,374)Cash and cash equivalents at beginning of the year 2,172,812 2,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,			000
Net increase (decrease) in cash and cash equivalents for the year 39,579 (173,374)Cash and cash equivalents at beginning of the year 2,172,812 2,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,			(2.2.2.2.2.2.)
Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,––	Net cash used in financing activities	(305,990)	(330,200)
Cash and cash equivalents at beginning of the year2,172,8122,349,021Effect of exchange rate changes of cash and cash equivalents–(2,835)Cash and cash equivalents at end of the year,––			
Effect of exchange rate changes of cash and cash equivalents – (2,835) Cash and cash equivalents at end of the year,	Net increase (decrease) in cash and cash equivalents for the year	39,579	(173,374)
Cash and cash equivalents at end of the year,	Cash and cash equivalents at beginning of the year	2,172,812	2,349,021
	Effect of exchange rate changes of cash and cash equivalents	-	(2,835)
	Cash and cash equivalents at end of the year,		
		2,212,391	2,172,812

For the year ended 31 December 2012

1. **GENERAL**

The Company is a listed company registered as an exempted company with limited liability in the Cayman Islands under the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands on 14 August 2002 and its shares have been listed on the Mainboard of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). Its ultimate holding company is Forway Investment Limited, a company incorporated in the British Virgin Islands ("BVI") with limited liability. The address of the registered office and principal place of business of the Company are disclosed in the "Corporate Information" section to the annual report.

The consolidated financial statements are presented in Renminbi ("RMB"), which is also the functional currency of the Company.

The Company acts as an investment holding company. The principal activities of its subsidiaries and associate are set out in the notes 33 and 15 to the consolidated financial statements, respectively.

2. APPLICATION OF NEW AND REVISED INTERNATIONAL FINANCIAL REPORTING STANDARDS ("IFRSs")

In the current year, the Group has applied the following amendments to IFRSs issued by the International Accounting Standards Board (the "IASB").

Amendments to IAS 12	Deferred tax: Recovery of underlying assets
Amendments to IFRS 7	Financial instruments: Disclosures – Transfers of financial assets

The adoption of the amendments to IFRSs has had no material effect on the consolidated financial statements of the Group for the current or prior accounting periods.

For the year ended 31 December 2012

2. APPLICATION OF NEW AND REVISED INTERNATIONAL FINANCIAL REPORTING STANDARDS (THE "IFRSs") (Continued)

New and revised IFRSs issued but not yet effective

The Group has not early applied the following new and revised IFRSs that have been issued but are not yet effective:

Amendments to IFRSs	Annual improvements to IFRSs 2009 – 2011 cycle ¹
Amendments to IFRS 7	Disclosures – Offsetting financial assets and financial liabilities ¹
Amendments to IFRS 9	Mandatory effective date of IFRS 9 and transition disclosures ³
and IFRS 7	
Amendments to IFRS 10,	Consolidated financial statements, joint arrangements
IFRS 11 and IFRS 12	and disclosure of interests in other entities: Transition guidance
Amendments to IFRS 10,	Investment entities ²
IFRS 12 and IAS 27	
IFRS 9	Financial instruments ³
IFRS 10	Consolidated financial statements ¹
IFRS 11	Joint arrangements ¹
IFRS 12	Disclosure of interests in other entities ¹
IFRS 13	Fair value measurement ¹
IAS 19 (as revised in 2011)	Employee benefits ¹
IAS 27 (as revised in 2011)	Separate financial statements ¹
IAS 28 (as revised in 2011)	Investments in associates and joint ventures ¹
Amendments to IAS 1	Presentation of items of other comprehensive income ⁴
Amendments to IAS 32	Offsetting financial assets and financial liabilities ²
IFRIC 20	Stripping costs in the production phase of a surface mine ¹

- ¹ Effective for annual periods beginning on or after 1 January 2013.
- ² Effective for annual periods beginning on or after 1 January 2014.
- ³ Effective for annual periods beginning on or after 1 January 2015.
- ⁴ Effective for annual periods beginning on or after 1 July 2012.

For the year ended 31 December 2012

2. APPLICATION OF NEW AND REVISED INTERNATIONAL FINANCIAL REPORTING STANDARDS (THE "IFRSs") (Continued)

New and revised standards on consolidation, joint arrangements, associates and disclosures

In May 2011, a package of five standards on consolidation, joint arrangements, associates and disclosures were issued, including IFRS 10, IFRS 11, IFRS 12, IAS 27 (as revised in 2011) and IAS 28 (as revised in 2011).

IFRS 10 replaces the parts of IAS 27 "Consolidated and separate financial statements" that deal with consolidated financial statements. SIC 12 "Consolidation – Special purpose entities" will be withdrawn upon the effective date of IFRS 10. Under IFRS 10, there is only one basis for consolidation, that is, control. In addition, IFRS 10 includes a new definition of control that contains three elements: (a) power over an investee, (b) exposure, or rights, to variable returns from its involvement with the investee, and (c) the ability to use its power over the investee to affect the amount of the investor's returns. Extensive guidance has been added in IFRS 10 to deal with complex scenarios.

IFRS 12 is a disclosure standard and is applicable to entities that have interests in subsidiaries, joint arrangements, associates and/or unconsolidated structured entities. In general, the disclosure requirements in IFRS 12 are more extensive than those in the current standards.

In July 2012, the amendments to IFRS 10 and IFRS 12 were issued to clarify certain transitional guidance on the application of these IFRSs for the first time.

The directors of the Company anticipate that these five standards will be adopted in the Group's consolidated financial statements for the annual period beginning 1 January 2013. The directors of the Company have assessed the control in respect of its subsidiaries and an associate under the new definition in the new and revised IFRSs. The directors of the Company anticipate that the application of these five standards will not have material impact on amounts in connection to subsidiaries and an associate of the Company currently reported in the consolidated financial statements.

Amendments to IAS 1 "Presentation of items of other comprehensive income"

The amendments to IAS 1 "Presentation of items of other comprehensive income" introduce new terminology for the statement of comprehensive income and income statement. Under the amendments to IAS 1, a "statement of comprehensive income" is renamed as a "statement of profit or loss and other comprehensive income". The amendments to IAS 1 also require items of other comprehensive income to be grouped into two categories: (a) items that will not be reclassified subsequently to profit or loss; and (b) items that may be reclassified subsequently to profit or loss when specific conditions are met. Income tax on items of other comprehensive income is required to be allocated on the same basis – the amendments do not change the option to present items of other comprehensive income either before tax or net of tax.

For the year ended 31 December 2012

2. APPLICATION OF NEW AND REVISED INTERNATIONAL FINANCIAL REPORTING STANDARDS (THE "IFRSs") (Continued)

Amendments to IAS 1 "Presentation of items of other comprehensive income" (Continued)

The amendments to IAS 1 are effective for annual periods beginning on or after 1 July 2012. The presentation of items of other comprehensive income will be modified accordingly when the amendments are applied in future accounting periods.

The directors of the Company anticipate that the application of the other new and revised IFRSs will have no material effect on the consolidated financial statements.

3. SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards. In addition, the consolidated financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on the Stock Exchange and by the Hong Kong Companies Ordinance.

The consolidated financial statements have been prepared under the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods.

The principal accounting policies are set out below.

Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries). Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

Income and expenses of subsidiaries acquired or disposed of during the year are included in the consolidated statement of comprehensive income from the effective date of acquisition and up to the effective date of disposal, as appropriate.

All intra-group transactions, balances, income and expenses are eliminated in full on consolidation.

Non-controlling interests in subsidiaries are presented separately from the Group's equity therein.

Allocation of total comprehensive income to non-controlling interests

Total comprehensive income and expense of a subsidiary is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Business combinations

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interests issued by the Group in exchange for control of the acquiree. Acquisition-related costs are generally recognised in profit or loss as incurred.

At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognised at their fair value at the acquisition date, except that:

- deferred tax assets or liabilities, and assets or liabilities related to employee benefit arrangements are recognised and measured in accordance with IAS 12 "Income taxes" and IAS 19 "Employee benefits" respectively;
- liabilities or equity instruments related to share-based payment arrangements of the acquiree or share-based payment arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 "Share-based payment" at the acquisition date; and
- assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 "Non-current assets held for sale and discontinued operations" are measured in accordance with that standard.

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any noncontrolling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after re-assessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer's previously held interest in the acquiree (if any), the excess is recognised immediately in profit or loss as a bargain purchase gain.

Non-controlling interests that are present ownership interests and entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially measured either at fair value or at the non-controlling interests' proportionate share of the recognised amounts of the acquiree's identifiable net assets. The choice of measurement basis is made on a transaction-by-transaction basis. Other types of non-controlling interests are measured at their fair value or, when applicable, on the basis specified in another standard.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Goodwill

Goodwill arising from an acquisition of a business is carried at cost less accumulated impairment losses, if any, and is presented separately in the consolidated statement of financial position.

For the purposes of impairment testing, goodwill is allocated to each of the Group's cash-generating units (or groups of cash-generating units) that is expected to benefit from the synergies of the combination.

A cash-generating unit to which goodwill has been allocated is tested for impairment annually or more frequently when there is indication that the unit may be impaired. For goodwill arising on an acquisition in a reporting period, the cash-generating unit to which goodwill has been allocated is tested for impairment before the end of that reporting period. If the recoverable amount of the cash-generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit on a pro-rata basis based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

On disposal of the relevant cash-generating unit, the attributable amount of goodwill is included in the determination of the amount of profit or loss on disposal.

Investments in associates

An associate is an entity over which the Group has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

The results and assets and liabilities of associates are incorporated in these consolidated financial statements using the equity method of accounting. The financial statements of associates used for equity accounting purposes are prepared using uniform accounting policies as those of the Group for like transactions and events in similar circumstances. Under the equity method, investments in associates are initially recognised in the consolidated statement of financial position at cost and adjusted thereafter to recognise the Group's share of the profit or loss and other comprehensive income of the associates. When the Group's share of losses of an associate exceeds the Group's interest in that associate (which includes any long-term interests that, in substance, form part of the Group's net investment in the associate), the Group discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of that associate.

Any excess of the cost of acquisition over the Group's share of the net fair value of the identifiable assets, liabilities and contingent liabilities of an associate recognised at the date of acquisition is recognised as goodwill, which is included within the carrying amount of the investment.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Investments in associates (Continued)

The requirements of IAS 39 are applied to determine whether it is necessary to recognise any impairment loss with respect to the Group's investment in an associate. When necessary, the entire carrying amount of the investment (including goodwill) is tested for impairment in accordance with IAS 36 "Impairment of assets" as a single asset by comparing its recoverable amount (higher of value in use and fair value less costs to sell) with its carrying amount. Any impairment loss recognised forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognised in accordance with IAS 36 to the extent that the recoverable amount of the investment subsequently increases.

Upon disposal of an associate that results in the Group losing significant influence over that associate, any retained investment is measured at fair value at that date and the fair value is regarded as its fair value on initial recognition as a financial asset in accordance with IAS 39. The difference between the previous carrying amount of the associate attributable to the retained interest and its fair value is included in the determination of the gain or loss on disposal of the associate. In addition, the Group accounts for all amounts previously recognised in other comprehensive income in relation to that associate on the same basis as would be required if that associate had directly disposed of the related assets or liabilities. Therefore, if a gain or loss on the disposal of the related assets or liabilities, the Group reclassifies the gain or loss from equity to profit or loss (as a reclassification adjustment) when it loses significant influence over that associate.

When a group entity transacts with its associate, profits and losses resulting from the transactions with the associate are recognised in the Group' consolidated financial statements only to the extent of interests in the associate that are not related to the Group.

Property, plant and equipment

Property, plant and equipment including buildings held for use in the production or supply of goods or services, or for administrative purposes (other than construction in progress as described below) are stated in the consolidated statement of financial position at cost less subsequent accumulated depreciation and accumulated impairment losses, if any.

Depreciation is recognised so as to write off the cost of items of property, plant and equipment other than construction in progress less their residual values over their estimated useful lives using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Property, plant and equipment (Continued)

Properties in the course of construction for production, supply or administrative purposes are carried at cost, less any recognised impairment loss. Costs include professional fees and, for qualifying assets, borrowing costs capitalised in accordance with the Group's accounting policy. Such properties are classified to the appropriate categories of property, plant and equipment when completed and ready for intended use. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

Financial instruments

Financial assets and financial liabilities are recognised in the consolidated statement of financial position when a group entity becomes a party to the contractual provisions of the instrument.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets or financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition.

Financial assets

The Group's financial assets comprise loans and receivables. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial asset and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset, or, where appropriate, a shorter period to the net carrying amount on initial recognition.

Interest income is recognised on an effective interest basis for debt instruments.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Subsequent to initial recognition, loans and receivables (including trade and other receivables, bills receivables, pledged bank deposits and bank balances and cash) are measured at amortised cost using the effective interest method, less any identified impairment losses (see accounting policy on impairment loss on financial assets below).

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Financial instruments (Continued)

Financial assets (Continued)

Impairment of financial assets

Financial assets are assessed for indicators of impairment at the end of the reporting period. Financial assets are considered to be impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the financial assets have been affected.

Objective evidence of impairment could include:

- significant financial difficulty of the issuer or counterparty; or
- breach of contracts, such as default or delinquency in interest or principal payments; or
- it becoming probable that the borrower will enter bankruptcy or financial re-organisation.

For certain categories of financial asset, such as trade and other receivables and bills receivables, assets that are assessed not to be impaired individually are subsequently assessed for impairment on a collective basis. Objective evidence of impairment for a portfolio of receivables could include the Group's past experience of collecting payments, an increase in the number of delayed payments in the portfolio past the average credit period normally ranging from six months to one year, observable changes in national or local economic conditions that correlate with default on receivables.

For financial assets carried at amortised cost, the amount of impairment loss recognised is the difference between the asset's carrying amount and the present value of the estimated future cash flows discounted at the financial asset's original effective interest rate.

The carrying amount of the financial asset is reduced by the impairment loss directly for all financial assets with the exception of trade receivables and bills receivables, where the carrying amount is reduced through the use of an allowance account. Changes in the carrying amount of the allowance account are recognised in profit or loss. When a trade receivable or bills receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited to profit or loss.

For financial assets measured at amortised cost, in a subsequent period, if the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment loss was recognised, the previously recognised impairment loss is reversed through profit or loss to the extent that the carrying amount of the asset at the date the impairment is reversed does not exceed what the amortised cost would have been had the impairment not been recognised.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Financial instruments (Continued)

Financial liabilities and equity

Financial liabilities and equity instruments issued by a group entity are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of the group entity after deducting all of its liabilities. Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Interest expense is recognised on an effective interest basis.

Financial liabilities

Financial liabilities including trade and other payables, bills payable and amount due to a related company are subsequently measured at amortised cost, using the effective interest method.

Derecognition

The Group derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity.

On derecognition of a financial asset in its entirely, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in profit or loss.

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or expires. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.

Operating lease payments are recognised as an expense on a straight-line basis over the term of the relevant lease.

Leasehold land and building

When a lease includes both land and building elements, the Group assesses the classification of each element as a finance or an operating lease separately based on the assessment as to whether substantially all the risks and rewards incidental to ownership of each element have been transferred to the Group, unless it is clear that both elements are operating leases in which case the entire lease is classified as an operating lease. Specifically, the minimum lease payments (including any lump-sum upfront payments) are allocated between the land and the building elements in proportion to the relative fair values of the leasehold interests in the land element and building element of the lease at the inception of the lease.

To the extent the allocation of the lease payments can be made reliably, interest in leasehold land that is accounted for as an operating lease is presented as "prepaid lease payments" in the consolidated statement of financial position and is amortised over the lease term on a straight-line basis.

Intangible assets

Intangible assets with finite useful lives that are acquired separately are carried at costs less accumulated amortisation and any accumulated impairment losses. Amortisation for intangible assets with finite useful lives is provided on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effective of any changes in estimate being accounted for on a prospective basis.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset are measured at the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in profit or loss in the period when the asset is derecognised.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Impairment losses on tangible and intangible assets other than goodwill (see the accounting policy in respect of goodwill above)

At the end of the reporting period, the Group reviews the carrying amounts of its tangible and intangible assets with finite useful life to determine whether there is any indication that those assets have suffered an impairment loss. If any such indicator exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or a cash-generating unit) is reduced to its recoverable amount. An impairment losses are recognised immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or a cash-generating unit) is increased to the revised estimate of its recoverable amount, but to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or a cash-generating unit) in prior years. A reversal of an impairment loss is recognised in profit or loss immediately.

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is calculated using the first-in, first-out method.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods sold in the normal course of business, net of discounts and sales related taxes.

Revenue from the sale of goods is recognised when the goods are delivered and titles have passed, at which time all the following conditions are satisfied:

- the Group has transferred to the buyer the significant risks and rewards of ownership of the goods;
- the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of revenue can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the Group; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Revenue recognition (Continued)

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts the estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Government grants

Government grants are not recognised until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received.

Government grants are recognised in profit or loss on a systematic basis over the periods in which the Group recognises as expenses the related costs for which the grants are intended to compensate. Specifically, government grants whose primary condition is that the Group should purchase, construct or otherwise acquire non-current assets are recognised as deferred income in the consolidated statement of financial position and transferred to profit or loss on a systematic and rational basis over the useful lives of the related assets.

Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognised in profit or loss in the period in which they become receivable.

Research and development expenditure

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

An internally-generated intangible asset arising from development activities (or from the development phase of an internal project) is recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Research and development expenditure (Continued)

The amount initially recognised for internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is charged to profit or loss in the period in which it is incurred. Subsequent to initial recognition, internally-generated intangible asset is measured at cost less accumulated amortisation and accumulated impairment losses (if any), on the same basis as intangible assets acquired separately.

Retirement benefit costs

Payments to defined contribution retirement benefit plans/stare-managed retirement benefit schemes are charged as an expense when employees have rendered service entitling them to the contributions.

Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from "profit before taxation" as reported in the consolidated statement of comprehensive income because it excludes items of income or expense that are taxable or deductible in other years, and it further excludes items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax base used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible temporary difference to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and associate, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

For the year ended 31 December 2012

3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Taxation (Continued)

The carrying amount of deferred tax assets is reviewed at the end of the reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset is realised, based on tax rate (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities. Current and deferred tax is recognised in profit or loss, except when it relates to items that are recognised in other comprehensive income or directly in equity, in which case the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.

Foreign currencies

In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recorded in the respective functional currency (i.e. the currency of the primary economic environment in which the entity operates) at the rates of exchanges prevailing on the dates of the transactions. At the end of the reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognised in profit or loss in the period in which they arise.

4. KEY SOURCES OF ESTIMATION UNCERTAINTY

The following is the key assumption concerning the future, and other key source of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets within the next financial year.

Estimated impairment of goodwill

Determining whether goodwill is impaired requires an estimation of the value in use of the cash-generating units to which goodwill has been allocated. The value in use calculation requires the Group to estimate the future cash flows expected to arise from the cash-generating unit and a suitable discount rate in order to calculate the present value. Where the actual future cash flows are less than expected, a material impairment loss may arise. As at 31 December 2012, the carrying amount of goodwill is RMB91,663,000 (2011: RMB91,663,000). Details of the recoverable amount calculation are disclosed in note 16.

For the year ended 31 December 2012

5. TURNOVER AND SEGMENT INFORMATION

Operating segments

The Group's operation was regarded as a single segment, being an enterprise engaged in research and development, manufacture and trading of Chinese pharmaceutical products. The Chairman of the Board of Directors of the Group, being the chief operating decision maker, reviews the revenue and the profit for the year of the Group as a whole for performance assessment and resource allocation. No analysis of segment assets or segment liabilities is presented as they are not regularly provided to the chief operating decision maker. Therefore, the operation of the Group constitutes one single reportable segment.

Revenue from major products

The following is an analysis of the Group's revenue from its major products:

	2012	2011
	RMB'000	RMB'000
Injections	1,238,486	1,142,468
Soft capsules	446,739	435,919
Granules	366,300	339,887
Others	80,724	66,268
	2,132,249	1,984,542

Geographical information

Sales of the Group to external customers were substantially made in the People's Republic of China (the "PRC") including Hong Kong.

All non-current assets of the Group including goodwill are located in the PRC including Hong Kong.

Information about major customers

For each of the year ended 31 December 2012 and 2011, there was no customer with turnover accounted for more than 10% of the Group's total turnover.

For the year ended 31 December 2012

6. INVESTMENT INCOME

	2012	2011
	RMB'000	RMB'000
Interest on bank deposits	31,553	41,114
Investment income from debt-related products (Note a)	6,070	3,135
Investment income from short-term debt-related products (Note b)	42,384	24,274
	80,007	68,523

Notes:

- (a) These debt related products were entered into and matured during the both years with effective interest rate ranged from 5.5% to 5.6% (2011: 3.5% to 4.5%) per annum.
- (b) These short-term debt related products were entered into and matured during the both years with effective interest rate ranged from 3.1% to 6.1% (2011: 3% to 5.9%) per annum. In the opinion of the directors of the Company, these short-term debt related products are in large amounts, with quick turnover and short maturities. Accordingly, the cash receipts and payments for these short-term debt related products are presented on a net basis in the consolidated statement of cash flows.

7. TAXATION

	2012	2011
	RMB'000	RMB′000
The charge comprise:		
Current tax – PRC Enterprise Income Tax		
Current year	123,965	174,416
(Over)underprovision in prior years	(8,306)	14,781
Withholding tax paid on distributed profits	36,583	23,981
	152,242	213,178
Deferred tax (note 17)	(161)	(19,254)
	152,081	193,924

For the year ended 31 December 2012

7. TAXATION (Continued)

The taxation charge for the year can be reconciled to the profit before taxation as follows:

2012 HK\$	2011
HK\$	
iπφ	HK\$
799,736	949,500
199,934	237,375
8,521	7,707
(3,087)	(2,636)
(73)	-
985	1,848
(85,821)	(93,070)
3,261	3,855
36,583	23,981
(8,306)	14,781
84	83
152,081	193,924
	799,736 199,934 8,521 (3,087) (73) 985 (85,821) 3,261 36,583 (8,306) 84

Hong Kong Profits Tax is calculated at 16.5% (2011: 16.5%) on the estimated assessable profits for the year. The Company and its subsidiaries operating in Hong Kong do not have assessable profits, accordingly, no provision for Hong Kong Profits Tax has been made in the consolidated financial statements.

The provision for PRC Enterprise Income Tax ("PRC EIT") is based on the estimated taxable income for PRC taxation purpose at the rate of taxation applicable for both years.

Under the Law of the PRC on EIT (the "EIT Law") and Implementation Regulation of the EIT Law, the tax rate of the PRC subsidiaries is 25%.

Certain subsidiaries which are operating in the Western China or recognised as High and New-tech Enterprise have been granted tax concessions by the local tax bureau and are entitled to PRC EIT at concessionary rate of 15% for both years. The tax concessions granted to certain subsidiaries operating in the Western China will expire in 2020.

Included in the current tax for the year ended 31 December 2011 was an amount of RMB18,667,000 in relation to a government grant received in 2010, which was recognised as deferred income as at 31 December 2010. During the year ended 31 December 2011, the tax authority imposed tax on such government subsidy. A corresponding deferred tax asset has been recognised during the year ended 31 December 2011 which will be reversed to profit or loss when the deferred income is recognised in the profit or loss.

For the year ended 31 December 2012

8. **PROFIT FOR THE YEAR**

	2012	2011
	RMB'000	RMB'000
Profit for the year has been arrived at after charging:		
Directors' emoluments (see note 9)	31,343	35,596
Other staff costs	142,495	118,002
Other staff's pension costs	44,204	36,834
	218,042	190,432
Amortisation of intangible assets	692	735
Amortisation of prepaid lease payments	3,629	3,608
Auditor's remuneration	1,528	1,860
Depreciation of property, plant and equipment	77,681	64,948
Loss on disposal of property, plant and equipment	39	105
Rental expenses under operating lease in respect of rented premises	2,430	2,433
and after crediting:		
Government subsidies (included in other income) (Note)	76,021	120,471
Reversal of allowance for bad and doubtful debts	-	1,963

Note: The government subsidies represent the amounts received from the local government by the subsidiaries of the Company. In 2012, government subsidies of (a) RMB71,901,000 (2011: RMB110,916,000) represent incentives received in relation to carrying out business operations in relevant regions in the PRC; and (b) RMB4,120,000 (2011: RMB9,555,000) represent recognition of deferred income upon completion of related research activities.

For the year ended 31 December 2012

9. DIRECTORS', CHIEF EXECUTIVE'S AND EMPLOYEES' REMUNERATION

Directors' and Chief executive's remuneration:

	Fees	Salaries, allowance and other benefits	Pension costs		Total remuneration
Year ended 31 December 2012	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Executive directors:					
	53	1 (10	0	27.000	20 (71
Li Zhenjiang Wang Zhihua	53 42	1,610 559	8 8	27,000	28,671 609
Xin Yunxia	42 52	693		-	753
Li Huimin			8	-	
	48	651	8	-	707
Brandelyn Lee Ching Ton	0	110	2		100
(appointed on 1 October 2012)	8	112	3	-	123
Independent non-executive					
directors:					
Sun Liutai	120	-	-	-	120
Cheng Li	120	-	-	-	120
Ren Dequan	120	-	-	-	120
Hung Randy King Kuen	120		-	-	120
	683	3,625	35	27,000	31,343
Year ended 31 December 2011					
Executive directors:					
Li Zhenjiang	52	1,572	_	31,500	33,124
Wang Zhihua	43	573	_	, 	616
Xin Yunxia	52	688	_	_	740
Li Huimin	47	646	-	-	693
Independent non-executive					
directors:					
Sun Liutai	118	_	-	_	118
Cheng Li	118	_	_	-	118
Ren Dequan	118	_	_	_	118
Hung Randy King Kuen	69	-	-	-	69
	617	3,479	_	31,500	35,596

Note: The performance related incentive payments were determined with reference to the individual performance for the year.

Mr. Li Zhenjiang is also the Chief Executive of the Company and his emoluments disclosed above included those for services rendered by him as Chief Executive.

For the year ended 31 December 2012

9. DIRECTORS', CHIEF EXECUTIVE'S AND EMPLOYEES' REMUNERATION (Continued)

Employees' remuneration:

The five highest paid individuals of the Group included 3 directors (2011: 3), details of whose remuneration are set out above. The remuneration of remaining 2 employees (2011: 2) is as follows:

	2012	2011
	RMB'000	RMB'000
Salaries, allowance and other benefits	2,208	1,764
Pension costs	28	19
	2,236	1,783

Emolument of the remaining 2 employees (2011: 2) are within the band ranging from HK\$1,000,001 to HK\$1,500,000.

During the year, no remuneration was paid by the Group to the directors or highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office. None of the directors has waived any remuneration during the year.

The remuneration of directors and key executives is determined by the remuneration committee having regard to the performance of individuals and market trends.

For the year ended 31 December 2012

10. DIVIDENDS

	2012	2011
	RMB'000	RMB'000
Dividends recognised as distributions during the year:		
Final dividend paid for 2011 of RMB12 cents		
(2010: RMB12 cents) per share	99,240	99,240
Special dividend paid for 2011 of RMB14 cents		
(2010: RMB17 cents) per share	115,780	140,590
Interim dividend paid for 2012 of RMB11 cents		
(2011: RMB11 cents) per share	90,970	90,970
	305,990	330,800
Dividends proposed:		
Proposed final dividend of RMB12 cents		
(2011: RMB12 cents) per share	99,240	99,240
Proposed special dividend of RMB9 cents	55,240	55,240
(2011: RMB14 cents) per share	74,430	115,780
	74,430	115,760
	173,670	215,020

The final dividend of RMB12 cents per share and special dividend of RMB9 cents per share (total: RMB21) have been proposed by the directors and is subject to approval by the shareholders in the general meeting.

For the year ended 31 December 2012

11. EARNINGS PER SHARE

The calculation of the basic earnings per share attributable to the owners of the Company is based on the following data:

	2012	2011
	RMB'000	RMB'000
Earnings for the purpose of basic earnings per share		
(profit for the year attributable to owners of the Company)	647,704	755,600

	Number of ordinary shares	
	2012	2011
Number of ordinary shares for the purpose of basic		
earnings per share	827,000,000	827,000,000

No diluted earnings per share is presented as the Company did not have any potential dilutive ordinary shares outstanding.

For the year ended 31 December 2012

12. PROPERTY, PLANT AND EQUIPMENT

	Buildings RMB'000	Plant and machineries RMB'000	Office equipment RMB'000	Motor vehicles RMB'000	Construction in progress RMB'000	Total RMB'000
COST						
At 1 January 2011	332,548	382,620	25,476	5,926	333,822	1,080,392
Currency realignment	_	_	(37)	_	_	(37)
Additions	4,013	20,363	6,219	189	365,794	396,578
Reclassifications	21,861	25,725	_	-	(47,586)	-
Disposals	-	(953)	(67)	(36)	-	(1,056)
At 31 December 2011	358,422	427,755	31,591	6,079	652,030	1,475,877
Currency realignment	, _	, 	(30)	-	, _	(30)
Additions	1,344	52,152	7,668	186	306,316	367,666
Reclassifications	242,753	119,878	2,361	15	(365,007)	_
Disposals	_	(1,783)	(239)	_	_	(2,022)
At 31 December 2012	602,519	598,002	41,351	6,280	593,339	1,841,491
DEPRECIATION						
At 1 January 2011	75,964	208,736	15,101	3,810	_	303,611
Currency realignment	-	_	(35)	-	_	(35)
Charge for the year	17,551	42,212	4,368	817	_	64,948
Eliminated on disposals	_	(858)	(59)	(34)	-	(951)
At 31 December 2011	93,515	250,090	19,375	4,593	_	367,573
Currency realignment	_	_	(28)	_	_	(28)
Charge for the year	22,012	49,859	5,153	657	_	77,681
Eliminated on disposals	_	(1,760)	(223)	_	_	(1,983)
At 31 December 2012	115,527	298,189	24,277	5,250	_	443,243
CARRYING VALUES						
At 31 December 2012	486,992	299,813	17,074	1,030	593,339	1,398,248
At 31 December 2011	264,907	177,665	12,216	1,486	652,030	1,108,304

For the year ended 31 December 2012

12. PROPERTY, PLANT AND EQUIPMENT (Continued)

The above items of property, plant and equipment, other than construction in progress, are depreciated over their estimated useful lives after taking into account their estimated residual values using the straight-line method as follows:

Buildings	20 years or over the unexpired lease terms,
	whichever is shorter
Plant and machineries	3 to 10 years
Office equipment	5 years
Motor vehicles	3 years

13. PREPAID LEASE PAYMENTS

	2012	2011
	RMB'000	RMB'000
Medium-term leasehold land in the PRC	151,482	153,901
Less: Amount charged within one year		
(included in other receivables)	(3,477)	(3,452)
	148,005	150,449

Movements of prepaid lease payments are as follows:

	2012	2011
	RMB'000	RMB'000
At 1 January	153,901	157,509
Addition during the year	1,210	_
Expense for the year	(3,629)	(3,608)
At 31 December	151,482	153,901

The lease term over which the prepaid lease payments are amortised ranged from 45 to 50 years.

For the year ended 31 December 2012

14. INTANGIBLE ASSETS

Movements of intangible assets are as follows:

	2012	2011
	RMB'000	RMB'000
At 1 January	1,430	2,165
Amortisation for the year	(692)	(735)
At 31 December	738	1,430

The intangible assets represent patents with finite useful lives. Such intangible assets are amortised on straight line basis over the useful lives from 2 to 20 years.

15. INTEREST IN AN ASSOCIATE

	2012	2011
	RMB'000	RMB'000
Cost of investment in an associate, unlisted	16,720	_
Share of post-acquisition profits	293	_
	17,013	_

Included in the cost of investment in an associate is goodwill of RMB4,409,000 arising on acquisition of 33.24% of registered capital of an associate from independent third parties for a total cash consideration of RMB16,720,000 during the year.

For the year ended 31 December 2012

15. INTEREST IN AN ASSOCIATE (Continued)

Details of the Group's associate at 31 December 2012 are as follows:

Name of associate	Form of business structure	Place of registration/ operations	Nominal value of registered capital	Attributa equity int to the G	erest	Principal activities
				2012	2011	
Jilin Jianjin Pharmaceutical Company Limited 吉林省健今蔡業股份 有限公司	Limited liability company	PRC	RMB35,200,000	33.24%	N/A	Manufacture and trading of Chinese pharmaceutical products

The associate is indirectly held by the Company.

The summarised financial information in respect of the Group's associate is set out below:

	2012	2011
	RMB'000	RMB'000
Total assets	75,856	-
Total liabilities	(37,939)	-
Net assets	37,917	-
Share of net assets	12,604	-
Turnover	81,045	-
Profit for the year	881	-
Share of profit of an associate	293	_

For the year ended 31 December 2012

16. GOODWILL

	2012	2011
	RMB'000	RMB'000
At 1 January and 31 December	91,663	91,663

The management annually determines if there is impairment of its cash-generating unit ("CGU") containing goodwill.

For the purpose of impairment testing, goodwill has been allocated to the CGU including six subsidiaries with principal activities of manufacturing and trading of Chinese pharmaceutical products. These six subsidiaries are Shineway Pharmaceutical Sales Company Limited, Shineway Pharmaceutical (Hainan) Company Limited, Xizang Shineway Pharmaceutical Company Limited, Shineway Pharmaceutical (Chengdu) Company Limited, Shineway Pharmaceutical (Zhangjiakou) Company Limited and Shineway Pharmaceutical (Sichuan) Company Limited. During the year ended 31 December 2012, management of the Group has determined that there is no impairment of its CGU containing goodwill.

The recoverable amount of the above CGU has been determined based on a value in use calculation. That calculation uses cash flow projections based on most recent financial budgets approved by management covering a five-year period, and discount rate of 12% (2011: 12%). Cash flows beyond the five-year period have been extrapolated using an estimated constant growth rate of 8% (2011: 8%) which does not exceed the average growth rate for the relevant markets. Other key assumptions for the value in use calculations relate to the estimation of cash inflows/outflows which include budgeted sales and gross margin, such estimation is based on the unit's past performance and management's expectations for the market development.

17. DEFERRED TAXATION

For the purpose of presentation in the consolidated statement of financial position, certain deferred tax assets and liabilities have been offset. The following is the analysis of the deferred tax balances for financial reporting purposes:

	2012	2011
	RMB'000	RMB'000
Deferred tax assets	25,924	25,825
Deferred tax liabilities	(1,014)	(1,076)
	24,910	24,749

For the year ended 31 December 2012

17. DEFERRED TAXATION (Continued)

The followings are the major deferred tax liabilities and assets recognised and movement thereon during the current and prior years.

	Accelerated			
	tax	Deferred		
	depreciation	income	Others	Total
	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2011	5,609	_	(114)	5,495
(Charge) credit to profit or loss	(146)	18,667	733	19,254
At 31 December 2011	5,463	18,667	619	24,749
(Charge) credit to profit or loss	(146)	_	307	161
At 31 December 2012	5,317	18,667	926	24,910

At the end of the reporting period, the Group has unused tax losses of approximately RMB94,026,000 (2011: RMB90,086,000) available for offset against future profits. No deferred tax asset has been recognised in respect of such tax losses due to the unpredictability of future profit streams. Unrecognised tax losses may be carried forward indefinitely.

Under the EIT Law of the PRC, withholding tax is imposed on dividends declared in respect of profits earned by PRC subsidiaries from 1 January 2008 onwards. Deferred taxation has not been provided for in the consolidated financial statements in respect of temporary differences attributable to accumulated profits of the PRC subsidiaries amounting to RMB2,329,945,000 (2011: RMB2,173,205,000) as the Group is able to control the timing of the reversal of the temporary differences and it is probable that the temporary differences will not reverse in the foreseeable future.

18. INVENTORIES

	2012	2011
	RMB'000	RMB'000
Raw materials	94,479	138,196
Work in progress	44,174	57,052
Finished goods	65,312	87,524
	203,965	282,772

All inventories were carried at cost at the end of the reporting period.

For the year ended 31 December 2012

19. TRADE AND BILLS RECEIVABLES

	2012	2011
	RMB'000	RMB'000
Trade receivables	20,509	13,521
Less: Allowance for doubtful debts	(124)	(124)
	20,385	13,397
Bills receivables	501,233	404,320
	521,618	417,717

The Group allows a credit period normally ranging from six months to one year to its trade customers. The following is an aged analysis of trade and bills receivables, net of allowance for doubtful debts, presented based on the invoice date at the end of the reporting period.

	2012	2011
	RMB'000	RMB'000
Within 6 months	521,556	417,717
Over 6 months but less than 1 year	62	-
	521,618	417,717
	521,010	417,71

Before accepting any new customer, the Group has appointed a special team to monitor the potential customer's credit quality and defines credit limits by customer, which are reviewed every year. Except for the allowance for doubtful debts amounting to RMB124,000 at 31 December 2012 and 2011, there is no other adverse change in the credit quality of the customers from the date of credit was initially granted. All of the trade and bills receivables are not past due.

Movement in allowance for doubtful debts

	2012	2011
	RMB'000	RMB'000
1 January	124	2,087
Reversal of allowance recognised	_	(1,963)
31 December	124	124

Included in the allowance for doubtful debts are individually impaired trade receivables with an aggregate balance of RMB124,000 (2011: RMB124,000) which have either been placed under liquidation or are in financial difficulties. The Group does not hold any collateral over these balances.

88 China Shineway Pharmaceutical Group Limited • Annual Report 2012

For the year ended 31 December 2012

20. PLEDGED BANK DEPOSITS

Pledged bank deposits of RMB19,860,000 (2011: RMB27,839,000) represent certain bank deposits pledged to banks to secure bills payables totalling RMB19,731,000 (2011: RMB27,839,000) issued by the Group. The pledged bank deposits carry fixed interest rate of 3.05% (2011: 3.3%) per annum. The pledged bank deposits will be released upon the settlement of the relevant bills payables.

21. BANK BALANCES AND CASH

Bank balances comprises short-term bank deposits. The effective interest rate ranged from 0.01% to 3.5% (2011: 0.39% to 3.1%) per annum as at 31 December 2012.

At the end of the reporting period, bank balances and cash of RMB2,155,943,000 (2011: RMB2,076,407,000) were denominated in RMB which is not a freely convertible currency in the international market. The exchange rate of RMB is regulated by the Government of the PRC and the remittance of these funds out of the PRC is subject to exchange restrictions imposed by the Government of the PRC.

Included in bank balances are the following amounts denominated in currencies other than the functional currency of the relevant group entity to which they relate.

	2012	2011
	RMB'000	RMB'000
Hong Kong Dollars	56,300	96,230
United States Dollars	148	175

22. TRADE AND BILLS PAYABLES

	2012	2011
	RMB'000	RMB'000
Trade payables	255,071	261,950
Bills payables	19,731	27,839
	274,802	289,789

For the year ended 31 December 2012

22. TRADE AND BILLS PAYABLES (Continued)

An aged analysis of the Group's trade and bills payables at the end of the reporting period is as follows:

	2012	2011
	RMB'000	RMB'000
Within 6 months	234,446	235,147
Over 6 months but less than 1 year	12,630	20,077
Over 1 year but less than 2 years	15,793	17,560
Over 2 years	11,933	17,005
	274,802	289,789

Trade and bills payables principally comprise amounts outstanding for trade purchases and ongoing costs. The average credit period taken for trade purchase ranges from two months to six months.

23. AMOUNT DUE TO A RELATED COMPANY

	2012	2011
	RMB'000	RMB'000
Shineway Medical Science & Technology (Lang Fang)		
Co., Ltd. ("Shineway Lang Fang")	9,009	9,009

Shineway Lang Fang is ultimately controlled by the controlling shareholder of the Group. The amount is unsecured, interest-free and repayable on demand.

24. **DEFERRED INCOME**

	2012	2011
	RMB'000	RMB'000
At 1 January	77,766	77,266
Addition during the year	20,789	10,055
Recognised as other income	(4,120)	(9,555)
At 31 December	94,435	77,766
Analysed for reporting purpose as		
Current liabilities	4,099	3,100
Non-current liabilities	90,336	74,666
	94,435	77,766

For the year ended 31 December 2012

24. DEFERRED INCOME (Continued)

Included in the deferred income at 31 December 2012 are government subsidies amounting to RMB19,769,000 (2011: RMB3,100,000) in relation to research and development expenses on certain new products not yet recognised. The subsidy is recognised as deferred income because there is an obligation to repay the subsidy if the related research is not successfully completed. The amount will be recognised in profit or loss when the related research is successfully completed. During the year, the Group received RMB20,789,000 (2011: RMB10,055,000) government subsidies in relation to research and development expenses and recognised RMB4,120,000 (2011: RMB9,555,000) in profit or loss as the related researches are successfully completed.

At 31 December 2012 and 2011, the deferred income included a government subsidy amounting to RMB74,666,000 received in 2010 in relation to a development project, including the construction of production premises and acquisition of plant and machineries, in the 邛崍醫藥產業園 ("Qionglai Pharmaceutical Area") in Sichuan Province in the PRC. The grant is recognised as deferred income and to be credited to profit or loss on a systematic basis over the useful lives of the related assets when the assets are ready for management's intended use. The Group has an obligation to repay the grant if the grant is not utilised for the development project. No deferred income is transferred to profit or loss as the related development project has not been completed at the end of the reporting period.

25. SHARE CAPITAL

	Number of shares '000	Amount
Ordinary shares of HK\$0.10 each		
Authorised:		
Balance at 1 January 2011, 31 December 2011		
and 31 December 2012	5,000,000	HK\$500,000,000
Issued and fully paid:		
Balance at 1 January 2011, 31 December 2011		
and 31 December 2012	827,000	HK\$82,700,000
Shown in the financial statement as	827,000	RMB87,662,000

26. CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure that entities in the Group will be able to continue as a going concern while maximising the return to shareholders. During the years ended 31 December 2012 and 2011, the Group has been generating operating profit to sustain its operation and development, as such, the Group has not raised external debt. The Group's overall strategy remains unchanged from prior year.

For the year ended 31 December 2012

26. CAPITAL RISK MANAGEMENT (Continued)

The capital structure of the Group consists of equity attributable to owners of the Company, comprising issued share capital and reserves during the years ended 31 December 2012 and 2011.

The Group actively and regularly reviews and manages its capital structure and makes adjustments to it in light of the changes in the Group's business and economic conditions.

27. FINANCIAL INSTRUMENTS

Categories of financial instruments

2012	2011
RMB'000	RMB'000
2,770,844	2,633,568
453,459	431,254
	RMB'000 2,770,844

Financial risk management objectives and policies

The Group's major financial instruments include trade and other receivables, bills receivables, pledged bank deposits, bank balances and cash, trade and other payables, bills payables, and amounts due to related companies. Details of the financial instruments are disclosed in respective notes. The risks associated with these financial instruments include market risk (foreign currency risk and interest rate risk), credit risk and liquidity risk. The policies on how to mitigate these risks are set out below. The management manages and monitors these exposures to ensure appropriate measures are implemented on a timely and effective manner.

Foreign currency risk

Several subsidiaries of the Company have foreign currency bank balances, which expose the Group to foreign currency risk. Approximately 3% (2011: 4%) of the Group's bank balances and cash are denominated in currencies other than the functional currency of the relevant group entities.

For the year ended 31 December 2012

27. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

Foreign currency risk (Continued)

Sensitivity analysis

The Group is mainly exposed to HKD as disclosed in note 21 with the functional currency of those subsidiaries in RMB.

The following table details the Group's sensitivity to a 5% (2011: 5%) increase and decrease in RMB against HKD. 5% (2011: 5%) are the sensitivity rates used which represents management's assessment of the reasonably possible change in relevant foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the year end for a 5% (2011: 5%) change in HKD. A negative number below indicates a decrease in profit for the year where RMB strengthens 5% (2011: 5%) against HKD. For a 5% weakening of RMB against HKD, there would be an equal and opposite impact on the profit for the year.

	HKD Impact	
	2012	2011
	RMB'000	RMB'000
Decrease in profit for the year	(2,111)	(3,609)

In management's opinion, the sensitivity analysis is unrepresentative of the interest foreign currency risk as the year end exposure does not reflect the exposure during the year.

Interest rate risk

Interest bearing financial assets are mainly bank deposits which are all short-term in nature and carry fixed interest rates. Therefore, the Group is not exposed to significant interest rate risk due to the short maturity of financial assets. The Group is also exposed to cash flow interest rate risk relates to short-term debt-related products and debt-related products entered into and matured during the year. The Group currently does not have an interest rate hedging policy. The directors of the Company continuously monitor interest rate exposure and will consider enter into interest rate hedging should the need arise.

The directors considered the Group's exposure of the short-term bank deposits to interest rate risk is not significant and therefore no sensitivity analysis is presented.

For the year ended 31 December 2012

27. FINANCIAL INSTRUMENTS (Continued)

Financial risk management objectives and policies (Continued)

Credit risk

The Group's maximum exposure to credit risk which will cause a financial loss to the Group due to failure to discharge an obligation by the counterparties is arising from the carrying amount of those financial assets as stated in the consolidated statement of financial position.

In order to minimise the credit risk, the management of the Group has delegated a team responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group reviews the recoverable amount of each individual bill, trade and other receivables at the end of the reporting period to ensure that adequate impairment losses are made for irrecoverable amounts. In this regard, the directors of the Company consider that the Group's credit risk is significantly reduced.

With respect to credit risk arising from the short-term debt-related products and debt-related products entered into and matured during the year, the directors of the Company considered that the Group's exposure to credit risk arising from default of the counterparties over the underlying assets of these products is limited as the investment decisions by the management of the Group are made with reference to the risk level of these products suggested by the banks and to the historical default rate of these products. The Group does not expect any significant loss on these products.

The Group's concentration of credit risk by geographical locations is mainly in PRC, which accounted for 98% (2011: 94%) of the total trade and bill receivables as at 31 December 2012.

The credit risk on bank deposits is limited because the counterparties are financial institutions with high credit standing.

Liquidity risk

The directors of the Company has built an appropriate liquidity risk management framework for the management of the Group's short, medium and long-term funding and liquidity management requirements. The Group manages liquidity risk by continuously monitoring forecasted and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The earliest date on which the Group can be required to pay the financial liabilities is less than 12 months from the end of the reporting period. The Group expects to have sufficient financial assets to settle its obligations within 12 months from the end of the reporting period.

For the year ended 31 December 2012

27. FINANCIAL INSTRUMENTS (Continued)

Fair value

The fair values of financial assets and financial liabilities are determined in accordance with generally accepted pricing models based on discounted cash flow analysis.

The directors of the Company consider that the carrying amounts of financial assets and financial liabilities recorded at amortised cost approximate their fair values.

28. SHARE OPTIONS

The Company's share option scheme (the "Scheme") was adopted pursuant to a resolution passed on 10 November 2004 for the primary purpose of providing incentives to:

- (a) director or employee of any members of the Group;
- (b) any discretionary object of a discretionary trust established by any substantial shareholder of the Company or employee of any member of the Group;
- (c) any consultant, professional and other advisers to any member of the Group;
- (d) any chief executive or substantial shareholder of any member of the Group;
- (e) any associate of any director, chief executive or substantial shareholder of any member of the Group; and
- (f) any employee (whether full-time or part-time) of substantial shareholder of any member of the Group to take up options.

The Scheme will expire on 9 November 2014. Under the Scheme, the Board of Directors of the Company may grant options to eligible person to subscribe for shares in the Company.

The total number of shares in respect of which options may be granted under the Scheme is not permitted to exceed 10% of the shares of the Company in issue at any point of time, without prior approval from the Company's shareholders. The number of shares issued and to be issued in respect of which options granted and may be granted to any individual in any one year is not permitted to exceed 1% of the shares of the Company in issue at any point in time, without prior approval from the Company's shareholders. Options granted to substantial shareholders, independent non-executive directors, or any of their respective associates (including a discretionary trust whose discretionary objects include a substantial shareholder or an independent non-executive director or a company beneficially owned by any substantial shareholder or independent non-executive director of the Company) in excess of 0.1% of the Company's shareholders.

For the year ended 31 December 2012

28. SHARE OPTIONS (Continued)

Option granted must be taken up within 14 days from the date of offer, upon payment of HK\$1 per option. Options may be exercised at any time from the date of grant of the share option to the 10 anniversary of the date of grant. The exercise price is determined by the directors of the Company, and will not be less than the higher of (i) the closing price of the Company's shares on the date of grant; (ii) the average closing price of the shares for the five business days immediately preceding the date of grant; and (iii) the nominal value of the Company's share.

No option has been granted since adoption of the Scheme.

29. OPERATING LEASE

At the end of the reporting period, the Group had commitments for future minimum lease payments under non-cancellable operating leases which fall due as follows:

	2012	2011
	RMB'000	RMB'000
Within one year	1,205	1,493
In the second to fifth year inclusive	-	1,044
	1,205	2,537

Operating lease payments represent rentals payable by the Group for certain of its warehouse, staff quarters and offices. Leases are negotiated for terms ranged from 1 to 3 years with fixed rental.

At 31 December 2012, included in the operating lease commitment, an amount of RMB619,000 (2011: RMB619,000) as fall due within one year is payable to Shineway Medical Science & Technology Co., Ltd ("Shineway Medical"), a company ultimately controlled by the controlling shareholder of the Group.

30. RETIREMENT BENEFITS PLANS

The employees of the Group participate in retirement and medicare insurances in accordance with the PRC laws and related regulations. When an employee joins the Group, he is enrolled with the local retirement plan. Contributions to the retirement insurance, borne by the Group and the employee jointly at the proportions stipulated by the local Municipal Government, are paid to the social insurance institutions monthly. When the employee retires, he receives his retirement funds from the insurance company directly and is also entitled to enjoy medical benefits after retirement provided by the insurance company. Other than the contributions, the Group has no obligation for any related retirement benefits.

The total expense recognised in the consolidated statement of comprehensive income of RMB44,239,000 (2011: RMB36,834,000) represents contributions payable to this plan by the Group at rates specified in the rules of the plan.

For the year ended 31 December 2012

31. CAPITAL COMMITMENTS

	2012	2011
	RMB'000	RMB'000
Capital expenditure in respect of acquisition of property,		
plant and equipment contracted for but not provided in		
the consolidated financial statements	625,653	554,989

32. RELATED PARTY TRANSACTIONS

During the year, the Group had the following significant transactions with related parties:

	2012	2011
	RMB'000	RMB'000
Rental expenditure to Shineway Medical	619	619
Service fee to Shineway Lang Fang	1,747	1,713
Service fee to Shineway Medical	6,802	6,668
Sale of goods to Hebei Shineway Chain		
Drugstores Co., Ltd ("Shineway Drugstores") (Note)	-	768

Note: Shineway Drugstores is ultimately controlled by the controlling shareholder of the Group.

Compensation of key management personnel

Remuneration paid for key management personnel include solely the directors of the Company as disclosed in note 9.

For the year ended 31 December 2012

33. SUBSIDIARIES

Details of the subsidiaries at 31 December 2012 and 2011 are as follows:

	Percentage					
	Place and date of incorporation/ establishment	Issued share fully paid/ registered capital	of equity interest held by the Company		Principal activities	
						Name of company
						2012
Yuan Da Investment Limited			Hong Kong	Share	100%	100%
	10 November 2009	– HK\$1				
Yuan Da International Limited	British Virgin Islands ("BVI")	Share	100%	100%	Investment holding	
遠大國際有限公司	20 November 2002	- US\$10,000				
Hong Zhan International Limited	BVI	Share	100%	100%	Investment holding	
宏展國際有限公司	20 November 2002	- US\$10,000				
Shineway Pharmaceutical Sales	PRC	Registered capital	100%	100%	Trading of Chinese	
Company Limited	3 March 2003 for	- RMB98,533,542			pharmaceutical products	
神威藥業營銷有限公司 (Note a)	a term of 30 years					
Shineway Pharmaceutical	PRC	Registered capital	100%	100%	Research and development,	
Company Limited	30 December 2003	- US\$25,000,000			manufacture and	
神威藥業有限公司 (Note b)	for a term of 30 years				trading of Chinese pharmaceutical products	
					phannaceutical products	
Hebei Shineway Pharmaceutical	PRC	Registered capital	100%	100%	Manufacture and	
Company Limited	30 December 2003	- US\$12,000,000			trading of Chinese	
河北神威藥業有限公司 (Note b)	for a term of 30 years				pharmaceutical products	
China Shineway Pharmaceutical	Hong Kong	Share	100%	100%	Trading of Chinese	
(Hong Kong) Company Limited	21 April 2004	– HK\$1			pharmaceutical products	
中國神威蔡業 (香港) 有限公司						
Xizang Shineway Pharmaceutical	PRC	Registered capital	100%	100%	Trading of Chinese	
Company Limited 西赫油成慈業方明公司 (Materia)	7 November 2006	- US\$1,250,000			pharmaceutical products	
西藏神威藥業有限公司 (Note b)	for a term of 10 years					

For the year ended 31 December 2012

33. SUBSIDIARIES (Continued)

Name of company	Place and date of incorporation/ establishment	Issued share fully paid/ registered capital	Percentage of equity interest held by the Company 2012 2011		Principal activities
Shineway Pharmaceutical (Hainan) Company Limited 神威藥業 (海南) 有限公司 (Note b)	PRC 21 May 2009 for a term of 10 years	Registered capital – US\$3,900,000	100%	100%	Trading of Chinese pharmaceutical products
Shineway Pharmaceutical (Chengdu) Company Limited (Note c) 神威藥業 (成都) 有限公司	PRC 25 December 2009	Registered capital – RMB5,000,000	100%	100%	Trading of Chinese pharmaceutical products
Shineway Pharmaceutical (Zhangjiakou) Company Limited (Note c) 神威藥業 (張家口) 有限公司	PRC 18 November 2002	Registered capital – RMB22,000,000	100%	100%	Manufacture and trading of Chinese pharmaceutical products
Shineway Pharmaceutical (Sichuan) Limited (formerly known as Sichuan Kalituo Pharmaceutical Limited) (Note c) 神威藥業 (四川) 有限公司 (formerly known as 四川康利托製藥有限公司)	PRC 15 September 2003	Registered capital – RMB15,000,000	100%	100%	Manufacture and trading of Chinese pharmaceutical products
Chengdu Kalituo Technology Company Limited (Note c) 成都康利托科技有限公司	PRC 4 December 2009	Registered capital – RMB20,000,000	100%	100%	Trading of Chinese pharmaceutical products
Shineway (Shijiazhuang) Chinese Medicine Prepared Herbs Limited (Note c) 神威藥業 (石家莊) 中藥飲片有限公司	PRC 19 November 2010	Registered capital – RMB3,000,000	100%	100%	Trading of Chinese pharmaceutical products

For the year ended 31 December 2012

33. SUBSIDIARIES (Continued)

Name of company	Place and date of incorporation/ establishment	Issued share fully paid/ registered capital	Percentage of equity interest held by the Company 2012 2011		Principal activities
Shineway Pharmaceutical (Minle) Modern Agricultural Limited (Note c) 神威藥業(民樂)現代農業有限公司	PRC 17 June 2011	Registered capital – RMB2,000,000	70%	70%	Trading of Chinese pharmaceutical products
Beijing Shineway Song Biotechnology Company Limited (Note c) 北京神威頌生物科技有限公司	PRC 12 January 2012	Registered capital – RMB10,000,000	100%	N/A	Manufacture and trading of Chinese pharmaceutical products
Hebei Tongshun Bioenergy Technology Limited (Note c) 河北通順生物質能源科技有限公司	PRC 20 September 2012	Registered capital – RMB10,000,000	100%	N/A	Manufacture and trading of Chinese pharmaceutical products

Notes:

(a) Become a foreign wholly-owned enterprise after the equity interest transfer with effect from 30 March 2005.

(b) Being foreign wholly-owned enterprises.

(c) Being PRC domestic enterprises.

Except for Yuan Da Investment Limited, Yuan Da International Limited and Hong Zhan International Limited, all other subsidiaries are indirectly held by the Company.